26
|
Itoh G, Takagane K, Fukushi Y, Kuriyama S, Umakoshi M, Goto A, Yanagihara K, Yashiro M, Tanaka M. Cancer-associated fibroblasts educate normal fibroblasts to facilitate cancer cell spreading and T cell suppression. Mol Oncol 2021; 16:166-187. [PMID: 34379869 PMCID: PMC8732346 DOI: 10.1002/1878-0261.13077] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2021] [Revised: 07/16/2021] [Accepted: 08/10/2021] [Indexed: 11/11/2022] Open
Abstract
In some tumors, a small number of cancer cells are scattered in a large fibrotic stroma. Here, we demonstrate a novel mechanism for expansion of pro‐tumor fibroblasts via cancer‐associated fibroblast (CAF)‐mediated education of normal fibroblasts (NFs). When NFs were incubated with conditioned medium from CAFs, the resulting CAF‐educated fibroblasts (CEFs) generated reactive oxygen species, which induced NF‐κB‐mediated expression of inflammatory cytokines and the extracellular matrix protein asporin (ASPN), while expression of a common CAF marker gene, α‐SMA, was not increased. ASPN further increased CEF expression of downstream molecules, including indoleamine 2,3‐dioxygenase 1 (IDO‐1), kynureninase (KYNU), and pregnancy‐associated plasma protein‐A (PAPP‐A). These CEFs induce cytocidal effects against CD8+ T cells and IGF‐I activation in cancer cells. CEFs were generated without cancer cells by the direct mixture of NFs and CAFs in mouse xenografts, and once CEFs were generated, they sequentially educated NFs, leading to continuous generation of CEFs. In diffuse‐type gastric cancers, ASPNhigh/IDO‐1high/KYNUhigh/α‐SMA− CEFs were located at the distal invading front. These CEFs expanded in the fibrotic stroma and caused dissemination of cancer cells. ASPN may therefore be a key molecule in facilitating tumor spreading and T‐cell suppression.
Collapse
|
27
|
Tatsuno S, Doi H, Okada W, Inoue E, Nakamura K, Sano K, Wada Y, Uehara T, Inada M, Nakamatsu K, Monzen K, Hosono M, Matsumoto K, Tanooka M, Tanaka M, Nishimura Y. PO-1173 Previous pneumectomy is a risk factor of severe radiation pneumonitis after IMRT for lung cancer. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07624-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
28
|
Kadoba K, Watanabe R, Iwasaki T, Kitagori K, Akizuki S, Murakami K, Nakashima R, Hashimoto M, Tanaka M, Ohmura K, Morinobu A, Terao C, Yoshifuji H. POS0345 CLINICOGENETIC STUDY OF FIVE NOVEL SUSCEPTIBILITY LOCI FOR TAKAYASU ARTERITIS: SUSCEPTIBILITY LOCI IN THE IL12B AND PTK2B REGION, BUT NOT THE LILRA3, DUSP22, KLHL33 REGIONS, ARE ASSOCIATED WITH VASCULAR DAMAGE IN TAKAYASU ARTERITIS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:We have previously identified single nucleotide polymorphism (SNP) rs6871626 in IL12B, rs103294 in LILRA3, rs17133698 in DUSP22, rs2322599 in PTK2B, and rs1713450 in KLHL33 as non-HLA susceptibility loci in Takayasu arteritis (TAK) [1, 2]. However, the association of these SNPs with clinical features has scarcely investigated.Objectives:In this study, we aimed to examine how these SNPs contribute to clinical features and vascular damage in TAK.Methods:We enrolled 99 TAK patients who were enrolled in our previous genome-wide association study (GWAS) [2]. To assess vascular damage, Takayasu Arteritis Damage Score (TADS) and Vasculitis Damage Index (VDI) were measured at the last visit before November 2020. As for organ damages, the presence or absence of aortic regurgitation (AR), hypertension, ischemic heart disease, cerebrovascular event, visual loss, end-stage renal failure, and inflammatory bowel disease were evaluated. Treatment profiles including immunosuppressive drugs and vascular interventions were also reviewed.Results:The incidence of AR was positively associated with the risk allele of IL12B rs6871626 (p=0.0052; odds ratio (OR) 2.45, 95% confidence interval (CI) 1.27-4.73), and so was the proportion of patients who underwent aortic valve replacement (p=0.023; OR 3.64, 95% CI 1.08-12.24) (table 1). The incidence of hypertension was associated with the risk allele of IL12B rs6871626 (p=0.049; OR 1.82, 95% CI 0.99-3.36) and PTK2B rs2322599 (p=0.044; OR 2.52, 95% CI 0.97-6.54) (table 1). The proportion of biologic users tended to be higher in the risk genotypes of IL12B rs6871626 (p=0.15; OR1.80, 95% CI 0.79-3.99). Regarding vascular damage, there was positive correlation between TADS and the risk allele of IL12B rs6871626 (p=0.0035; β= 1.35) (Figure 1). Moreover, VDI was also positively correlated with the allele (p=0.0054; β= 0.96) (Figure 1). No other clinicogenetic associations were observed between five SNPs and vasculitis-associated damages.Table 1.The association of the five SNPs with aortic regurgitation and hypertensionAortic regurgitationHypertensionOR (95% CI)p valueOR (95% CI)p valueIL12B rs68716262.45 (1.27-4.73)0.0052*1.82 (0.99-3.36)0.049*PTK2B rs23225991.21 (0.51-2.86)0.672.51 (0.97-6.54)0.044*LILRA3 rs1032941.16 (0.52-2.61)0.711.20 (0.55-1.64)0.64DUSP22 rs171336980.56 (0.28-1.13)0.0900.87 (0.46-1.63)0.66KLHL33 rs17134500.89 (0.42-1.91)0.771.48 (0.68-3.22)0.31SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence intervalConclusion:In the present study, IL12B rs6871626 was closely correlated with vascular damage. We also found association between PTK2B rs2322599 and hypertension. There was no significant relevance between vascular damage and LILRA3 rs103294, DUSP22 rs17133698, or KLHL33 rs1713450.References:[1]Terao C et al. Am J Hum Genet. 2013;93(2):289-97.[2]Terao C et al. Proc Natl Acad Sci U S A. 2018;115(51):13045-50.Disclosure of Interests:Keiichiro Kadoba: None declared, Ryu Watanabe Speakers bureau: I have received speaker’s fee from Mitsubishi Tanabe Pharma, Pfizer, Sanofi, AbbVie, Asahi Kasei, Eisai, Eli Lilly, Bristol-Myers Squibb, and Janssen., Takeshi Iwasaki: None declared, Koji Kitagori Grant/research support from: KK has received research grants from GlaxoSmithKline., Syuji Akizuki: None declared, Kosaku Murakami Speakers bureau: I have received speaking fees from Eisai Co. Ltd, Chugai Pharmaceutical Co. Ltd., Pfizer Inc., Bristol-Myers Squibb, Mitsubishi Tanabe Pharma Corporation, UCB Japan Co. Ltd, Daiichi Sankyo Co. Ltd. and Astellas Pharma Inc., Ran Nakashima: None declared, Motomu Hashimoto Speakers bureau: I have received a research grant and/or speaker fee from Bristol-Myers, Eisai, Ely Lilly, Mitsubishi Tanabe Pharma., Grant/research support from: I have received a research grant and/or speaker fee from Bristol-Myers, Eisai, Ely Lilly, Mitsubishi Tanabe Pharma., Masao Tanaka Speakers bureau: I have received research grants and/or speaker fees from AbbVie GK, Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly and Company, Pfizer Inc., UCB Japan Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K., Taisho Pharma Co., Ltd, and Takeda Pharmaceutical Company Limited., Koichiro Ohmura Speakers bureau: I have received speaker’s fee from Abbvie, Actelion, Asahikasei Pharma, Astellas, AYUMI, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, GSK, Janssen, JB, Mitsubishi Tanabe, Nippon Kayaku, Nippon Shinyaku, Novartis, Sanofi and Takeda., Grant/research support from: I have received research grants from GlaxoSmithKline., Akio Morinobu Speakers bureau: I have received speaking fees from Chugai Pharmaceutical Co. Ltd., Grant/research support from: I have received research grants from Chugai Pharmaceutical Co. Ltd., Chikashi Terao: None declared, Hajime Yoshifuji Speakers bureau: I have received lecture fees from Chugai., Consultant of: I have been an advisory board for a clinical trial conducted by Janssen.
Collapse
|
29
|
Yoshida T, Hashimoto M, Murakami K, Murata K, Nishitani K, Watanabe R, Koyama T, Uehara R, Tanaka M, Ito H, Matsuda S. POS1482-HPR PAIN CATASTROPHIZING IS ASSOCIATED WITH RESIDUAL PAIN AFTER REACHING IMPROVED CONDITIONS OF SWOLLEN/TENDER JOINTS AND SERUM C-REACTIVE PROTEIN LEVEL. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:It has long been recognized that immune-mediated inflammatory diseases, such as rheumatoid arthritis (RA), are prone to coexist with depression due to the effects of cytokines, and that these two illnesses lead to an elevation in patients’ pain. However, we often encounter patients with RA who suffer from residual pain despite an improvement in disease activity and inflammation. The specific psychological factors associated with residual pain have not yet been clarified. In addition to the traditional psychological factors, such as depression and anxiety, we focused on pain catastrophizing due to the distortion of pain perception and explored its association with residual pain.Objectives:To examine whether psychological factors, such as pain catastrophizing, depression, and anxiety, are associated with self-reported pain visual analogue scale (pain-VAS) scores in RA patients with 1 or less on 28joints- swollen/tender counts (SJC/TJC) and CRP.Methods:This was a cross-sectional study of 290 RA outpatients (85% of whom were women) with scores of less than 1 on SJC, TJC, and CRP, with a median (IQR) age of 66 (57–73) years. The participants completed questionnaires, including pain VAS (0–100 mm), Pain Catastrophizing Scale (PCS, 0–52 scale), and Hospital Depression and Anxiety Scale (HADS, 0–42 scale). Using linear regression analyses, we analysed whether PC (PCS ≥30), depression (HADS-D ≥11), and anxiety (HADS-A ≥11) (independent variables) were associated with pain VAS scores (dependent variable). After univariate regression analysis, multivariate analysis adjusted for confounding factors was performed.Results:Patients reported a wide range of pain severity with a median (range) pain VAS score of 9 (0–96mm). The prevalence of anxiety and depression were 5.5% and 5.9%, respectively. Meanwhile, 24.1% of the patients experienced pain catastrophizing. Pain catastrophizing was associated with pain VAS scores in univariate and multivariate analyses (Table 1). The presence of anxiety and depression was not associated with pain VAS scores in any model. Multivariate analysis of other covariates showed that age, disease duration, and presence of SJC/TJC of joints other than the 28 joints were positively correlated with pain VAS scores.Table 1.Univariate and multivariate regression analysis for independent variables associated with pain-VAS scoresUnivariateMultivariate independent variablesModel 1*Model 2**Pain catastrophizingEstimate3.74.13.695%CI 0.7 to 6.61.1 to 7.00.5 to 6.6p-value0.0150.0060.021AnxietyEstimate3.74.40.595%CI -1.9 to 9.2 -1.0 to 9.9 -3.5 to 7.9p value0.1980.1080.453DepressionEstimate3.54.23.995%CI -1.9 to 8.9 -1.1 to 9.5 -1.9 to 8.7p-value0.2040.1190.210The covariates in multivariate analysis are as follows: age, sex, body mass index, disease duration, Steinbrocker’s Stage, prednisolone dosage, biologic agents use, and presence of swollen joint counts/tender joint counts of joints other than the 28 joints.*Model 1: each psychological independent variable and the above covariates.**Model 2: all psychological independent variables and the above covariates.Conclusion:Pain catastrophizing was associated with pain VAS scores in RA patients with 1 or less on 28joints-SJC/TJC and CRP, emphasising that residual pain in the patients should be treated in a biopsychosocial framework focussing on pain catastrophizing.Disclosure of Interests:Tamami Yoshida: None declared, Motomu Hashimoto Speakers bureau: Mitsubishi Tanabe Pharma Corporation; Bristol-Myers Squibb; Eisai Co., Ltd.; and Eli Lilly and Company., Grant/research support from: Mitsubishi Tanabe Pharma Corporation; Bristol-Myers Squibb; Eisai Co., Ltd.; and Eli Lilly and Company., Kosaku Murakami Speakers bureau: Eisai Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Pfizer Inc.; Bristol-Myers Squibb; Mitsubishi Tanabe Pharma Co; UCB Japan Co., Ltd.; Daiichi Sankyo Co., Ltd.; and Astellas Pharma Inc., Consultant of: Eisai Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Pfizer Inc.; Bristol-Myers Squibb; Mitsubishi Tanabe Pharma Co; UCB Japan Co., Ltd.; Daiichi Sankyo Co., Ltd.; and Astellas Pharma Inc., Koichi Murata Speakers bureau: Eisai Co., Ltd. and Astellas Pharma Inc., Consultant of: Eisai Co., Ltd. and Astellas Pharma Inc., Kohei Nishitani Grant/research support from: Asahi-Kasei Pharma., Ryu Watanabe Speakers bureau: Mitsubishi Tanabe Pharma Co; Pfizer Inc.; Sanofi S.A.; AbbVie GK; Asahi Kasei Pharma; Eisai Co., Ltd.; Eli Lilly and Company; Bristol-Myers Squibb; and Janssen Pharmaceutical K.K., Teruhide Koyama: None declared, Ritei Uehara: None declared, Masao Tanaka Speakers bureau: AbbVie GK, Asahi Kasei Pharma., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Novartis Pharma K.K., Pfizer Inc., Taisyo Pharma., Ltd., UCB Japan Co., Ltd., Grant/research support from: AbbVie GK, Asahi Kasei Pharma., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Novartis Pharma K.K., Pfizer Inc., Taisyo Pharma., Ltd., UCB Japan Co., Ltd., Hiromu Ito Grant/research support from: Bristol-Myers Squibb, Eisai Co, Taisyo Pharma., and Mochida., Shuichi Matsuda: None declared
Collapse
|
30
|
Katsushima M, Minamino H, Torii M, Hashimoto M, Yamamoto W, Watanabe R, Murakami K, Murata K, Tanaka M, Ito H, Morinobu A. POS0544 INFLUENCE OF EATING HABITS ON FRAILTY AMONG PATIENTS WITH RHEUMATOID ARTHRITIS: KURAMA COHORT. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Rheumatoid arthritis (RA) is a chronic inflammatory disorder that contributes to accelerating frailty, a clinical state of increased vulnerability due to declined physiological function. Although accumulating evidence suggests the importance of nutritional therapy for frailty in the general population, there is little evidence on dietary recommendations for preventing frailty in patients with RA.Objectives:The present study aimed to reveal clinical associations between frailty status, eating habits and RA disease activity.Methods:We conducted a cross-sectional study of 306 female outpatients enrolled from the KURAMA (Kyoto University Rheumatoid Arthritis Management Alliance) cohort database. The participants were classified into three groups (robust, prefrail and frail) according to simplified frailty scale (SOF index), and dietary data were collected using a self-reported food frequency questionnaire as previously reported. We performed multivariate logistic analyses for the presence of frailty/prefrailty with or without eating habits.Results:Frail group showed physical decline such as decreased skeletal muscle index, hand grip strength and walking speed, and DAS28-ESR in the frail group was significantly higher compared to that in the others. In multivariate logistic analysis, the presence of frailty/prefrailty was correlated with DAS28-ESR (OR 1.71, p=0.00004) and methotrexate use (OR 0.47, p=0.0097). Cochran-Armitage trend test also showed that the intake frequency of five ingredients (meat, fish, milk, fruits and vegetables) was inversely associated with the prevalence of frailty/prefrailty. In additional multivariate logistic analyses with dietary habits, habitual intake of fish (at least three times per week), rather than meat or other foods, was independently correlated with the presence of frailty/prefrailty (OR 0.33, p=0.00027).Conclusion:Our results suggest that habitual intake of fish, rather than meat or other foods, may be beneficial in preventing frailty among RA patients.References:[1]Ferrucci, L. & Fabbri, E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol 15, 505-522, doi:10.1038/s41569-018-0064-2 (2018).[2]Hernandez Morante, J. J., Gomez Martinez, C. & Morillas-Ruiz, J. M. Dietary factors associated with frailty in old adults: a review of nutritional interventions to prevent frailty development. Nutrients 11, doi:10.3390/nu11010102 (2019).Table 1.Multivariate logistic analysis for RA patients with prefrailty or frailtyvariables including eating habitsFish + MeatAllOR (95% CI)P valueOR (95% CI)P valueDAS28-ESR1.78 (1.34 - 2.37)0.000031.73 (1.30 - 2.30)0.00009MTX use0.43 (0.23 - 0.79)0.00550.42 (0.23 - 0.78)0.0050Age (1 year)1.02 (1.00 - 1.05)0.0371.03 (1.01 - 1.06)0.0015PSL use1.23 (0.69 - 2.21)0.491.22 (0.67 - 2.20)0.51Duration of RA (1 year)1.00 (0.98 - 1.02)0.721.00 (0.98 - 1.02)0.84Body mass index1.00 (0.93 - 1.07)0.980.99 (0.92 - 1.07)0.85Biological agents use1.02 (0.60 - 1.72)0.941.04 (0.62 - 1.77)0.87Fish dish0.31 (0.17 - 0.55)0.000040.33 (0.18 - 0.61)0.00027Meat dish0.86 (0.49 - 1.50)0.600.89 (0.51 - 1.57)0.69Milk0.71 (0.41 - 1.24)0.23Vegetable0.95 (0.47 - 1.93)0.89Fruits0.77 (0.41 - 1.42)0.40Figure 1.The prevalence of prefrailty or frailty for subjects by intake frequencyAcknowledgements:We thank S. Nakagawa and M. Iida for technical assistance.Disclosure of Interests:Masao Katsushima: None declared, Hiroto Minamino: None declared, Mie Torii: None declared, Motomu Hashimoto Speakers bureau: M.H. receives grants and/or speaker fees from Bristol-Meyers, Eisai, Eli Lilly, and Tanabe Mitsubishi., Grant/research support from: M.H. belongs to the department financially supported by Nagahama City, Shiga, Japan, Toyooka City, Hyogo, Japan and five pharmaceutical companies (Tanabe-Mitsubishi, Chugai, UCB Japan, Ayumi and Asahi-Kasei).KURAMA cohort study is supported by a grant from Daiichi Sankyo Co. Ltd., Wataru Yamamoto: None declared, Ryu Watanabe Grant/research support from: R.W. belongs to the department that is financially supported by Nagahama City, Shiga, Japan, Toyooka City, Hyogo, Japan and five pharmaceutical companies (Tanabe-Mitsubishi, Chugai, UCB Japan, Ayumi and Asahi-Kasei). KURAMA cohort study is supported by a grant from Daiichi Sankyo Co. Ltd., Kosaku Murakami: None declared, Koichi Murata Grant/research support from: K.M. belongs to the department that is financially supported by Nagahama City, Shiga, Japan, Toyooka City, Hyogo, Japan and five pharmaceutical companies (Tanabe-Mitsubishi, Chugai, UCB Japan, Ayumi and Asahi-Kasei).KURAMA cohort study is supported by a grant from Daiichi Sankyo Co. Ltd., Masao Tanaka Grant/research support from: M.T. belongs to the department that is financially supported by Nagahama City, Shiga, Japan, Toyooka City, Hyogo, Japan and five pharmaceutical companies (Tanabe-Mitsubishi, Chugai, UCB Japan, Ayumi and Asahi-Kasei).KURAMA cohort study is supported by a grant from Daiichi Sankyo Co. Ltd., Hiromu Ito Speakers bureau: H.I. receives a research grant and/or speaker fee from Bristol-Myers, Eisai, Mochida, Taisho, and Asahi-Kasei., Grant/research support from: H.I. belongs to the department that is financially supported by Nagahama City, Shiga, Japan, Toyooka City, Hyogo, Japan and five pharmaceutical companies (Tanabe-Mitsubishi, Chugai, UCB Japan, Ayumi and Asahi-Kasei). KURAMA cohort study is supported by a grant from Daiichi Sankyo Co. Ltd., Akio Morinobu Speakers bureau: A.M. has received speaking fees and/or research grants from Eli Lilly Japan K.K., Ono Pharmaceutical Co., Pfizer Inc., UCB Japan, AbbVie G.K., Asahi Kasei Pharma and Chugai Pharmaceutical Co. Ltd., Grant/research support from: A.M. has received speaking fees and/or research grants from Eli Lilly Japan K.K., Ono Pharmaceutical Co., Pfizer Inc., UCB Japan, AbbVie G.K., Asahi Kasei Pharma and Chugai Pharmaceutical Co. Ltd.
Collapse
|
31
|
Masuzaki S, Yajima M, Ogawa K, Motojima G, Tanaka M, Tokitani M, Isobe M, Otsuka T. Investigation of the distribution of remaining tritium in divertor in LHD. NUCLEAR MATERIALS AND ENERGY 2021. [DOI: 10.1016/j.nme.2020.100884] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
32
|
Nagayoshi Y, Chujo T, Hirata S, Nakatsuka H, Chen CW, Takakura M, Miyauchi K, Ikeuchi Y, Carlyle BC, Kitchen RR, Suzuki T, Katsuoka F, Yamamoto M, Goto Y, Tanaka M, Natsume K, Nairn AC, Suzuki T, Tomizawa K, Wei FY. Loss of Ftsj1 perturbs codon-specific translation efficiency in the brain and is associated with X-linked intellectual disability. SCIENCE ADVANCES 2021; 7:7/13/eabf3072. [PMID: 33771871 PMCID: PMC7997516 DOI: 10.1126/sciadv.abf3072] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/17/2020] [Accepted: 02/09/2021] [Indexed: 05/06/2023]
Abstract
FtsJ RNA 2'-O-methyltransferase 1 (FTSJ1) gene has been implicated in X-linked intellectual disability (XLID), but the molecular pathogenesis is unknown. We show that Ftsj1 is responsible for 2'-O-methylation of 11 species of cytosolic transfer RNAs (tRNAs) at the anticodon region, and these modifications are abolished in Ftsj1 knockout (KO) mice and XLID patient-derived cells. Loss of 2'-O-methylation in Ftsj1 KO mouse selectively reduced the steady-state level of tRNAPhe in the brain, resulting in a slow decoding at Phe codons. Ribosome profiling showed that translation efficiency is significantly reduced in a subset of genes that need to be efficiently translated to support synaptic organization and functions. Ftsj1 KO mice display immature synaptic morphology and aberrant synaptic plasticity, which are associated with anxiety-like and memory deficits. The data illuminate a fundamental role of tRNA modification in the brain through regulation of translation efficiency and provide mechanistic insights into FTSJ1-related XLID.
Collapse
|
33
|
Sasaki Y, Takagane K, Konno T, Itoh G, Kuriyama S, Yanagihara K, Yashiro M, Yamada S, Murakami S, Tanaka M. Expression of asporin reprograms cancer cells to acquire resistance to oxidative stress. Cancer Sci 2021; 112:1251-1261. [PMID: 33393151 PMCID: PMC7935789 DOI: 10.1111/cas.14794] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2020] [Revised: 12/28/2020] [Accepted: 12/30/2020] [Indexed: 12/21/2022] Open
Abstract
Asporin (ASPN), a small leucine‐rich proteoglycan expressed predominantly by cancer associated fibroblasts (CAFs), plays a pivotal role in tumor progression. ASPN is also expressed by some cancer cells, but its biological significance is unclear. Here, we investigated the effects of ASPN expression in gastric cancer cells. Overexpression of ASPN in 2 gastric cancer cell lines, HSC‐43 and 44As3, led to increased migration and invasion capacity, accompanied by induction of CD44 expression and activation of Rac1 and MMP9. ASPN expression increased resistance of HSC‐43 cells to oxidative stress by reducing the amount of mitochondrial reactive oxygen species. ASPN induced expression of the transcription factor HIF1α and upregulated lactate dehydrogenase A (LDHA) and PDH‐E1α, suggesting that ASPN reprograms HSC‐43 cells to undergo anaerobic glycolysis and suppresses ROS generation in mitochondria, which has been observed in another cell line HSC‐44PE. By contrast, 44As3 cells expressed high levels of HIF1α in response to oxidant stress and escaped apoptosis regardless of ASPN expression. Examination of xenografts in the gastric wall of ASPN–/– mice revealed that growth of HSC‐43 tumors with increased micro blood vessel density was significantly accelerated by ASPN; however, ASPN increased the invasion depth of both HSC‐43 and 44As3 tumors. These results suggest that ASPN has 2 distinct effects on cancer cells: HIF1α‐mediated resistance to oxidative stress via reprogramming of glucose metabolism, and activation of CD44‐Rac1 and MMP9 to promote cell migration and invasion. Therefore, ASPN may be a new therapeutic target in tumor fibroblasts and cancer cells in some gastric carcinomas.
Collapse
|
34
|
Abe K, Bronner C, Hayato Y, Ikeda M, Imaizumi S, Ito H, Kameda J, Kataoka Y, Miura M, Moriyama S, Nagao Y, Nakahata M, Nakajima Y, Nakayama S, Okada T, Okamoto K, Orii A, Pronost G, Sekiya H, Shiozawa M, Sonoda Y, Suzuki Y, Takeda A, Takemoto Y, Takenaka A, Tanaka H, Yano T, Akutsu R, Han S, Kajita T, Okumura K, Tashiro T, Wang R, Xia J, Bravo-Berguño D, Labarga L, Marti L, Zaldivar B, Blaszczyk F, Kearns E, Gustafson J, Raaf J, Stone J, Wan L, Wester T, Bian J, Griskevich N, Kropp W, Locke S, Mine S, Smy M, Sobel H, Takhistov V, Weatherly P, Hill J, Kim J, Lim I, Park R, Bodur B, Scholberg K, Walter C, Coffani A, Drapier O, El Hedri S, Giampaolo A, Gonin M, Mueller T, Paganini P, Quilain B, Ishizuka T, Nakamura T, Jang J, Learned J, Anthony L, Sztuc A, Uchida Y, Berardi V, Catanesi M, Radicioni E, Calabria N, Machado L, De Rosa G, Collazuol G, Iacob F, Lamoureux M, Ospina N, Ludovici L, Nishimura Y, Cao S, Friend M, Hasegawa T, Ishida T, Kobayashi T, Matsubara T, Nakadaira T, Jakkapu M, Nakamura K, Oyama Y, Sakashita K, Sekiguchi T, Tsukamoto T, Nakano Y, Shiozawa T, Suzuki A, Takeuchi Y, Yamamoto S, Ali A, Ashida Y, Feng J, Hirota S, Ichikawa A, Kikawa T, Mori M, Nakaya T, Wendell R, Yasutome K, Fernandez P, McCauley N, Mehta P, Pritchard A, Tsui K, Fukuda Y, Itow Y, Menjo H, Niwa T, Sato K, Tsukada M, Mijakowski P, Posiadala-Zezula M, Jung C, Vilela C, Wilking M, Yanagisawa C, Harada M, Hagiwara K, Horai T, Ishino H, Ito S, Koshio Y, Ma W, Piplani N, Sakai S, Kuno Y, Barr G, Barrow D, Cook L, Goldsack A, Samani S, Simpson C, Wark D, Nova F, Boschi T, Di Lodovico F, Molina Sedgwick S, Taani M, Zsoldos S, Yang J, Jenkins S, McElwee J, Thiesse M, Thompson L, Malek M, Stone O, Okazawa H, Kim S, Yu I, Nishijima K, Koshiba M, Ogawa N, Iwamoto K, Yokoyama M, Martens K, Vagins M, Kuze M, Izumiyama S, Tanaka M, Yoshida T, Inomoto M, Ishitsuka M, Matsumoto R, Ohta K, Shinoki M, Martin J, Tanaka H, Towstego T, Hartz M, Konaka A, de Perio P, Prouse N, Pointon B, Chen S, Xu B, Richards B, Jamieson B, Walker J, Minamino A, Okamoto K, Pintaudi G, Sasaki R. Neutron-antineutron oscillation search using a 0.37 megaton-years exposure of Super-Kamiokande. Int J Clin Exp Med 2021. [DOI: 10.1103/physrevd.103.012008] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
35
|
Sato M, Hirose K, Ichise K, Yoshino H, Harada T, Hatayama Y, Kawaguchi H, Tanaka M, Fujioka I, Takai Y, Aoki M. Not Only Hypoxia- but Radiation-Induced Epithelial-Mesenchymal Transition Is Modulated by Hypoxia-Inducible Factor 1 in A549 Lung Cancer Cells. Folia Biol (Praha) 2021; 67:62-69. [PMID: 34624938] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Hypoxia leads to post-treatment metastasis and recurrences of cancer via the epithelial-mesenchymal transition (EMT). Radiotherapy itself may also contribute to the acquisition of EMT phenotypes. Despite extensive studies on the EMT driven by either hypoxia or radiation stimuli, the molecular mechanisms characterizing these EMT events remain unclear. Thus, we aimed to evaluate the differences in the molecular pathways between hypoxia-induced EMT (Hypo-EMT) and radiation-induced EMT (R-EMT). Further, we investigated the therapeutic effects of HIF-1α inhibitor (LW6) on Hypo-EMT and R-EMT cells. A549 cells, lung adenocarcinoma cell line, acquired enhanced wound-healing activity under both hypoxia and irradiation. Localization of E-cadherin was altered from the cell membrane to the cytoplasm in both hypoxia and irradiated conditions. Of note, the expression levels of vimentin, one of the major EMT markers, was enhanced in irradiated cells, while it decreased under hypoxia condition. Importantly, LW6 significantly blocked EMT-related malignant phenotypes in both Hypo-EMT cells and R-EMT cells with concomitant re-location of E-cadherin onto the cell membrane. Moreover, LW6 deflected stress responsive signalling, JNK, activated sustainably under hypoxic condition, and the blockage of JNK impaired EMT phenotypes. Together, this work demonstrated the molecular events underlying Hypo-EMT and R-EMT, and highlighted HIF-1α as a therapeutic target not only in Hypo- EMT, but also in R-EMT.
Collapse
|
36
|
Koyama Y, Migita S, Yamada S, Mukaiyama T, Amazaki H, Tanaka M, Okumura Y, Hao H. Pathology of critical limb ischemia; comparison of plaque characteristics between anterior and posterior tibial arteries. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
37
|
Yamamoto N, Seto T, Nishio M, Goto K, Yamamoto N, Okamoto I, Yamanaka T, Tanaka M, Takahashi K, Fukuoka M. Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study. Lung Cancer 2020; 151:20-24. [PMID: 33279874 DOI: 10.1016/j.lungcan.2020.11.020] [Citation(s) in RCA: 56] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2020] [Revised: 11/12/2020] [Accepted: 11/13/2020] [Indexed: 10/23/2022]
Abstract
OBJECTIVES The JO25567 randomized Phase II study demonstrated a statistically significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared with erlotinib monotherapy in chemotherapy-naïve Japanese patients with epidermal growth factor receptor mutation-positive (EGFR+) non-small-cell lung cancer (NSCLC). Here we present updated PFS and final overall survival (OS) data after a median follow-up of 34.7 months. MATERIALS AND METHODS Patients with stage IIIB/IV or postoperative recurrent NSCLC were randomized to receive oral erlotinib 150 mg once daily (n = 77) or erlotinib in combination with intravenous bevacizumab 15 mg/kg every 21 days (n = 75) until disease progression or unacceptable toxicity. OS was analyzed using an unstratified Cox proportional hazards model. RESULTS Consistent with the primary analysis, addition of bevacizumab to erlotinib was associated with a significant improvement in PFS (hazard ratio [HR] 0.52; 95 % confidence interval [CI]: 0.35-0.76; log-rank two-sided P = 0.0005; median 16.4 months vs 9.8 months, respectively). In contrast, a significant improvement in OS was not seen (HR 0.81; 95 % CI, 0.53-1.23; P = 0.3267; median 47.0 months vs 47.4 months, respectively). Post-study therapy was similar between the treatment arms and EGFR mutation type did not affect OS outcomes. The 5-year OS rate was numerically higher with erlotinib plus bevacizumab vs erlotinib monotherapy (41 % vs 35 %). Updated safety analyses confirmed the previously reported manageable tolerability profile, with no new safety issues. CONCLUSION Addition of bevacizumab to first-line erlotinib did not show significant improvement in OS in Japanese patients with stage IIIB/IV or postoperative recurrent EGFR+ NSCLC. Both treatment arms showed a similar median OS benefit (as long as 4 years), irrespective of individual patient characteristics. Results from ongoing studies evaluating the combination of EGFR and VEGF signaling inhibitors are eagerly awaited. TRIAL REGISTRATION JapicCTI-111390 and JapicCTI-142569.
Collapse
|
38
|
Tanaka M, Shizuta S, Komasa A, Yoshizawa T, Kohjitani H, Kimura T. Sex differences and arrhythmia recurrence after catheter ablation for atrial fibrillation. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Several previous studies reported female sex is associated with high recurrence rate of atrial tachyarrhythmia (ATA) after catheter ablation (CA) for atrial fibrillation (AF).
Purpose
We investigated the relationship between sex differences and recurrence rate of ATA after CA for AF in a large single-center database.
Methods
We enrolled consecutive 2033 patients undergoing first time CA for AF in our institution between Feb.2004 and Dec. 2017.
We compared the long-term outcomes between female (N=603) and male (N=1430).
Results
Female patients were older (70.8 vs. 66.3, p<0.0001), and had lower prevalence of persistent AF (23.1% vs. 33.5%, p<0.0001). Also, left atrial dimension was smaller (40.0 vs. 41.1, p=0.0005). and prior antiarrhythmic drug use was more prevalent (38.2% vs. 28.7%, p<0.0001) in female patients.
Ablation method for pulmonary vein isolation (PVI) was radiofrequency catheter ablation in 1634 patients (80.4%) and cryoballoon ablation in 399 (20.6%).
Median follow-up duration was 1342±115 days. The 3-year ATA recurrence rate after first CA was 35.8% overall: 39.9% in female and 34.2% in male (Log-rank P=0.01).
A multivariate analysis revealed that the factors associated with higher ATA recurrence rate were female (p=0.01), persistent AF (p=0.006), and larger left atrial dimension (p=0.007).
Conclusions
Female gender is an independent predictor of arrhythmia recurrence after CA for AF.
Funding Acknowledgement
Type of funding source: None
Collapse
|
39
|
Tanaka M, Shizuta S, Inoue K, Kobori A, Kaitani K, Yamaji H, Morishima I, Morimoto T, Kimura T. Predictive factors of recurrent atrial tachyarrhythmia after multiple procedures of radiofrequency catheter ablation for paroxysmal atrial fibrillation: Kansai Plus Atrial Fibrillation Registry (KPAF). Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The predictors of arrhythmia recurrence after radiofrequency catheter ablation (RFCA) for paroxysmal atrial fibrillation (PAF) have not yet been fully evaluated.
Purpose
The aim of this study was to develop and validate a risk scoring system to predict the incidence of recurrence of atrial tachyarrhythmia after the final RFCA for PAF.
Methods
The study population consisted of 3223 consecutive patients undergoing first-time RFCA for PAF from November 2011 to March 2014 in 26 cardiovascular centers in Japan who were enrolled in the Kansai Plus Atrial Fibrillation (KPAF) registry. We developed a scoring system in a derivation cohort with 2149 patients and assessed its reproducibility in a validation cohort with 1074 patients. The primary endpoint was recurrent atrial tachyarrhythmia lasting for ≥30 seconds after 91 days post the final ablation.
Results
During a median follow-up period of 3.1 years, 404 (18.8%) patients of the derivation cohort had AF recurrence after the final RFCA. The baseline patient characteristics of the derivation cohort were as follows: mean age 64.7 years, male 1480 (68.9%), mean body mass index (BMI) 23.6 kg/m2, hypertension 1122 (52.2%), prior heart failure 182 (8.5%), diabetes mellitus 203 (9.5%), prior stroke and/or transient ischemic attack 21 (1.0%), prior vascular disease 209 (9.7%), prior valvular disease 105 (4.9%), median CHADS2 score 1.1, median CHA2DS2-VASc score 2.1, mean number of ineffective antiarrhythmic drugs (AAD) 0.80, median duration of history of AF episodes 2.1 years, mean left atrial diameter (LAD) 38.2 mm, mean left ventricular ejection fraction (LVEF) 65.3%, and mean eGFR 68.7 mL/min/1.73m2. There was no significant difference in the baseline characteristics between derivation and validation cohorts. The results of the multivariate logistic regression models identified 5 independent variables of recurrent atrial tachyarrhythmia after the final RFCA: female (odds ratio (OR) = 1.45, p=0.0017), BMI <25 kg/m2 (OR=1.40, p=0.0081), duration of AF history 3 years≤ (OR=1.39, p<0.0034), chronic kidney disease (CKD) (OR=2.1, p=0.005, for stage 2/3CKD, OR=2.6, p=0.018 for stage 4/5 CKD), and LVEF (OR=2.1, p=0.039 for LVEF <50%, OR=1.5, p=0.022 for LVEF 50–60%). The predictive score for each factor was 3 points for CKD stage 4/5, 2 for CKD stage2/3 and LVEF <50%, and 1for the others (11 points in total). The arrhythmia-free rates after the final RCFA in the derivation cohort according to the score were as follows: 0–2 points = 91.7%, 3–4 = 80.7%, 5< = 72.6%, respectively. The similar results were reproduced in the validation cohort (Figure 1).
Conclusion
Our newly developed scoring system, composed of female, BMI, AF duration, CKD, and LVEF, could reproducibly predict arrhythmia recurrence after the final RFCA for PAF.
Funding Acknowledgement
Type of funding source: None
Collapse
|
40
|
Tanaka M, Fujishiro Y, Mogi M, Kaneko Y, Yokosawa T, Kanazawa N, Minami S, Koretsune T, Arita R, Tarucha S, Yamamoto M, Tokura Y. Topological Kagome Magnet Co 3Sn 2S 2 Thin Flakes with High Electron Mobility and Large Anomalous Hall Effect. NANO LETTERS 2020; 20:7476-7481. [PMID: 32897724 DOI: 10.1021/acs.nanolett.0c02962] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Magnetic Weyl semimetals attract considerable interest not only for their topological quantum phenomena but also as an emerging materials class for realizing quantum anomalous Hall effect in the two-dimensional limit. A shandite compound Co3Sn2S2 with layered kagome-lattices is one such material, where vigorous efforts have been devoted to synthesize the two-dimensional crystal. Here, we report a synthesis of Co3Sn2S2 thin flakes with a thickness of 250 nm by chemical vapor transport method. We find that this facile bottom-up approach allows the formation of large-sized Co3Sn2S2 thin flakes of high-quality, where we identify the largest electron mobility (∼2600 cm2 V-1 s-1) among magnetic topological semimetals, as well as the large anomalous Hall conductivity (∼1400 Ω-1 cm-1) and anomalous Hall angle (∼32%) arising from the Berry curvature. Our study provides a viable platform for studying high-quality thin flakes of magnetic Weyl semimetal and stimulate further research on unexplored topological phenomena in the two-dimensional limit.
Collapse
|
41
|
|
42
|
Aad G, Abbott B, Abbott D, Abdinov O, Abed Abud A, Abeling K, Abhayasinghe D, Abidi S, AbouZeid O, Abraham N, Abramowicz H, Abreu H, Abulaiti Y, Acharya B, Achkar B, Adachi S, Adam L, Adam Bourdarios C, Adamczyk L, Adamek L, Adelman J, Adersberger M, Adiguzel A, Adorni S, Adye T, Affolder A, Afik Y, Agapopoulou C, Agaras M, Aggarwal A, Agheorghiesei C, Aguilar-Saavedra J, Ahmadov F, Ahmed W, Ai X, Aielli G, Akatsuka S, Åkesson T, Akilli E, Akimov A, Al Khoury K, Alberghi G, Albert J, Alconada Verzini M, Alderweireldt S, Aleksa M, Aleksandrov I, Alexa C, Alexandre D, Alexopoulos T, Alfonsi A, Alhroob M, Ali B, Alimonti G, Alison J, Alkire S, Allaire C, Allbrooke B, Allen B, Allport P, Aloisio A, Alonso A, Alonso F, Alpigiani C, Alshehri A, Alvarez Estevez M, Álvarez Piqueras D, Alviggi M, Amaral Coutinho Y, Ambler A, Ambroz L, Amelung C, Amidei D, Amor Dos Santos S, Amoroso S, Amrouche C, An F, Anastopoulos C, Andari N, Andeen T, Anders C, Anders J, Andreazza A, Andrei V, Anelli C, Angelidakis S, Angerami A, Anisenkov A, Annovi A, Antel C, Anthony M, Antonelli M, Antrim D, Anulli F, Aoki M, Aparisi Pozo J, Aperio Bella L, Arabidze G, Araque J, Araujo Ferraz V, Haddad N, Hadef A, Hageböck S, Hagihara M, Haleem M, Haley J, Halladjian G, Hallewell G, Hamacher K, Hamal P, Araujo Pereira R, Hamano K, Hamdaoui H, Hamity G, Han K, Han L, Han S, Hanagaki K, Hance M, Handl D, Haney B, Arcangeletti C, Hankache R, Hansen E, Hansen J, Hansen J, Hansen M, Hansen P, Hanson E, Hara K, Hard A, Harenberg T, Arce A, Harkusha S, Harrison P, Hartmann N, Hasegawa Y, Hasib A, Hassani S, Haug S, Hauser R, Havener L, Havranek M, Arduh F, Hawkes C, Hawkings R, Hayden D, Hayes C, Hayes R, Hays C, Hays J, Hayward H, Haywood S, He F, Arguin JF, Heath M, Hedberg V, Heelan L, Heer S, Heidegger K, Heidorn W, Heilman J, Heim S, Heim T, Heinemann B, Argyropoulos S, Heinrich J, Heinrich L, Heinz C, Hejbal J, Helary L, Held A, Hellesund S, Helling C, Hellman S, Helsens C, Arling JH, Henderson R, Heng Y, Henkelmann S, Henriques Correia A, Herbert G, Herde H, Herget V, Hernández Jiménez Y, Herr H, Herrmann M, Armbruster A, Herrmann T, Herten G, Hertenberger R, Hervas L, Herwig T, Hesketh G, Hessey N, Higashida A, Higashino S, Higón-Rodriguez E, Armitage L, Hildebrand K, Hill E, Hill J, Hill K, Hiller K, Hillier S, Hils M, Hinchliffe I, Hinterkeuser F, Hirose M, Armstrong A, Hirose S, Hirschbuehl D, Hiti B, Hladik O, Hlaluku D, Hoad X, Hobbs J, Hod N, Hodgkinson M, Hoecker A, Arnaez O, Hoenig F, Hohn D, Hohov D, Holmes T, Holzbock M, Hommels L, Honda S, Honda T, Hong T, Hönle A, Arnold H, Hooberman B, Hopkins W, Horii Y, Horn P, Horyn L, Hostiuc A, Hou S, Hoummada A, Howarth J, Hoya J, Artamonov A, Hrabovsky M, Hrdinka J, Hristova I, Hrivnac J, Hrynevich A, Hryn’ova T, Hsu P, Hsu SC, Hu Q, Hu S, Artoni G, Huang Y, Hubacek Z, Hubaut F, Huebner M, Huegging F, Huffman T, Huhtinen M, Hunter R, Huo P, Hupe A, Artz S, Huseynov N, Huston J, Huth J, Hyneman R, Hyrych S, Iacobucci G, Iakovidis G, Ibragimov I, Iconomidou-Fayard L, Idrissi Z, Asai S, Iengo P, Ignazzi R, Igonkina O, Iguchi R, Iizawa T, Ikegami Y, Ikeno M, Iliadis D, Ilic N, Iltzsche F, Asbah N, Introzzi G, Iodice M, Iordanidou K, Ippolito V, Isacson M, Ishino M, Ishitsuka M, Islam W, Issever C, Istin S, Asimakopoulou E, Ito F, Iturbe Ponce J, Iuppa R, Ivina A, Iwasaki H, Izen J, Izzo V, Jacka P, Jackson P, Jacobs R, Asquith L, Jaeger B, Jain V, Jäkel G, Jakobi K, Jakobs K, Jakobsen S, Jakoubek T, Jamieson J, Janas K, Jansky R, Assamagan K, Janssen J, Janus M, Janus P, Jarlskog G, Javadov N, Javůrek T, Javurkova M, Jeanneau F, Jeanty L, Jejelava J, Astalos R, Jelinskas A, Jenni P, Jeong J, Jeong N, Jézéquel S, Ji H, Jia J, Jiang H, Jiang Y, Jiang Z, Atkin R, Jiggins S, Jimenez Morales F, Jimenez Pena J, Jin S, Jinaru A, Jinnouchi O, Jivan H, Johansson P, Johns K, Johnson C, Atkinson M, Jon-And K, Jones R, Jones S, Jones S, Jones T, Jongmanns J, Jorge P, Jovicevic J, Ju X, Junggeburth J, Atlay N, Juste Rozas A, Kaczmarska A, Kado M, Kagan H, Kagan M, Kahra C, Kaji T, Kajomovitz E, Kalderon C, Kaluza A, Atmani H, Kamenshchikov A, Kanjir L, Kano Y, Kantserov V, Kanzaki J, Kaplan L, Kar D, Kareem M, Karentzos E, Karpov S, Augsten K, Karpova Z, Kartvelishvili V, Karyukhin A, Kashif L, Kass R, Kastanas A, Kataoka Y, Kato C, Katzy J, Kawade K, Avolio G, Kawagoe K, Kawaguchi T, Kawamoto T, Kawamura G, Kay E, Kazanin V, Keeler R, Kehoe R, Keller J, Kellermann E, Avramidou R, Kelsey D, Kempster J, Kendrick J, Kepka O, Kersten S, Kerševan B, Ketabchi Haghighat S, Khader M, Khalil-Zada F, Khandoga M, Ayoub M, Khanov A, Kharlamov A, Kharlamova T, Khoda E, Khodinov A, Khoo T, Khramov E, Khubua J, Kido S, Kiehn M, Azoulay A, Kilby C, Kim Y, Kimura N, Kind O, King B, Kirchmeier D, Kirk J, Kiryunin A, Kishimoto T, Kisliuk D, Azuelos G, Kitali V, Kivernyk O, Kladiva E, Klapdor-Kleingrothaus T, Klassen M, Klein M, Klein M, Klein U, Kleinknecht K, Klimek P, Baca M, Klimentov A, Klingl T, Klioutchnikova T, Klitzner F, Kluit P, Kluth S, Kneringer E, Knoops E, Knue A, Kobayashi D, Bachacou H, Kobayashi T, Kobel M, Kocian M, Kodys P, Koenig P, Koffas T, Köhler N, Koi T, Kolb M, Koletsou I, Bachas K, Komarek T, Kondo T, Kondrashova N, Köneke K, König A, Kono T, Konoplich R, Konstantinides V, Konstantinidis N, Konya B, Backes M, Kopeliansky R, Koperny S, Korcyl K, Kordas K, Koren G, Korn A, Korolkov I, Korolkova E, Korotkova N, Kortner O, Backman F, Kortner S, Kosek T, Kostyukhin V, Kotwal A, Koulouris A, Kourkoumeli-Charalampidi A, Kourkoumelis C, Kourlitis E, Kouskoura V, Kowalewska A, Bagnaia P, Kowalewski R, Kozakai C, Kozanecki W, Kozhin A, Kramarenko V, Kramberger G, Krasnopevtsev D, Krasny M, Krasznahorkay A, Krauss D, Bahmani M, Kremer J, Kretzschmar J, Krieger P, Krieter F, Krishnan A, Krizka K, Kroeninger K, Kroha H, Kroll J, Kroll J, Bahrasemani H, Krstic J, Kruchonak U, Krüger H, Krumnack N, Kruse M, Krzysiak J, Kubota T, Kuchinskaia O, Kuday S, Kuechler J, Bailey A, Kuehn S, Kugel A, Kuhl T, Kukhtin V, Kukla R, Kulchitsky Y, Kuleshov S, Kulinich Y, Kuna M, Kunigo T, Bailey V, Kupco A, Kupfer T, Kuprash O, Kurashige H, Kurchaninov L, Kurochkin Y, Kurova A, Kurth M, Kuwertz E, Kuze M, Baines J, Kvam A, Kvita J, Kwan T, La Rosa A, La Rotonda L, La Ruffa F, Lacasta C, Lacava F, Lack D, Lacker H, Bajic M, Lacour D, Ladygin E, Lafaye R, Laforge B, Lagouri T, Lai S, Lammers S, Lampl W, Lampoudis C, Lançon E, Bakalis C, Landgraf U, Landon M, Lanfermann M, Lang V, Lange J, Langenberg R, Lankford A, Lanni F, Lantzsch K, Lanza A, Baker O, Lapertosa A, Laplace S, Laporte J, Lari T, Lasagni Manghi F, Lassnig M, Lau T, Laudrain A, Laurier A, Lavorgna M, Bakker P, Lazzaroni M, Le B, Le Guirriec E, LeBlanc M, LeCompte T, Ledroit-Guillon F, Lee C, Lee G, Lee L, Lee S, Bakshi Gupta D, Lee S, Lefebvre B, Lefebvre M, Legger F, Leggett C, Lehmann K, Lehmann N, Lehmann Miotto G, Leight W, Leisos A, Balaji S, Leite M, Leitgeb C, Leitner R, Lellouch D, Leney K, Lenz T, Lenzi B, Leone R, Leone S, Leonidopoulos C, Baldin E, Leopold A, Lerner G, Leroy C, Les R, Lester C, Levchenko M, Levêque J, Levin D, Levinson L, Lewis D, Balek P, Li B, Li B, Li CQ, Li F, Li H, Li H, Li J, Li K, Li L, Li M, Balli F, Li Q, Li Q, Li S, Li X, Li Y, Li Z, Liang Z, Liberti B, Liblong A, Lie K, Balunas W, Liem S, Lin C, Lin K, Lin T, Linck R, Lindon J, Lionti A, Lipeles E, Lipniacka A, Lisovyi M, Balz J, Liss T, Lister A, Litke A, Little J, Liu B, Liu B, Liu H, Liu H, Liu J, Liu J, Banas E, Liu K, Liu M, Liu P, Liu Y, Liu Y, Liu Y, Livan M, Lleres A, Llorente Merino J, Lloyd S, Bandyopadhyay A, Lo C, Lo Sterzo F, Lobodzinska E, Loch P, Loffredo S, Lohse T, Lohwasser K, Lokajicek M, Long J, Long R, Banerjee S, Longo L, Looper K, Lopez J, Lopez Paz I, Lopez Solis A, Lorenz J, Lorenzo Martinez N, Losada M, Lösel P, Lösle A, Bannoura A, Lou X, Lou X, Lounis A, Love J, Love P, Lozano Bahilo J, Lu M, Lu Y, Lubatti H, Luci C, Barak L, Lucotte A, Luedtke C, Luehring F, Luise I, Luminari L, Lund-Jensen B, Lutz M, Lynn D, Lysak R, Lytken E, Barbe W, Lyu F, Lyubushkin V, Lyubushkina T, Ma H, Ma L, Ma Y, Maccarrone G, Macchiolo A, Macdonald C, Machado Miguens J, Barberio E, Madaffari D, Madar R, Mader W, Madysa N, Maeda J, Maekawa K, Maeland S, Maeno T, Maerker M, Maevskiy A, Barberis D, Magerl V, Magini N, Mahon D, Maidantchik C, Maier T, Maio A, Maj K, Majersky O, Majewski S, Makida Y, Barbero M, Makovec N, Malaescu B, Malecki P, Maleev V, Malek F, Mallik U, Malon D, Malone C, Maltezos S, Malyukov S, Barillari T, Mamuzic J, Mancini G, Mandić I, Manhaes de Andrade Filho L, Maniatis I, Manjarres Ramos J, Mankinen K, Mann A, Manousos A, Mansoulie B, Barisits MS, Manthos I, Manzoni S, Marantis A, Marceca G, Marchese L, Marchiori G, Marcisovsky M, Marcon C, Marin Tobon C, Marjanovic M, Barkeloo J, Marshall Z, Martensson M, Marti-Garcia S, Martin C, Martin T, Martin V, Martin dit Latour B, Martinelli L, Martinez M, Martinez Outschoorn V, Barklow T, Martin-Haugh S, Martoiu V, Martyniuk A, Marzin A, Maschek S, Masetti L, Mashimo T, Mashinistov R, Masik J, Maslennikov A, Barnea R, Mason L, Massa L, Massarotti P, Mastrandrea P, Mastroberardino A, Masubuchi T, Matakias D, Matic A, Mättig P, Maurer J, Barnes S, Maček B, Maximov D, Mazini R, Maznas I, Mazza S, Mc Kee S, McCarthy T, McClymont L, McCormack W, McDonald E, Barnett B, Mcfayden J, McKay M, McLean K, McMahon S, McNamara P, McNicol C, McPherson R, Mdhluli J, Meadows Z, Meehan S, Barnett R, Megy T, Mehlhase S, Mehta A, Meideck T, Meirose B, Melini D, Mellado Garcia B, Mellenthin J, Melo M, Meloni F, Barnovska-Blenessy Z, Melzer A, Menary S, Mendes Gouveia E, Meng L, Meng X, Menke S, Meoni E, Mergelmeyer S, Merkt S, Merlassino C, Baroncelli A, Mermod P, Merola L, Meroni C, Meshkov O, Meshreki J, Messina A, Metcalfe J, Mete A, Meyer C, Meyer J, Barone G, Meyer JP, Meyer Zu Theenhausen H, Miano F, Michetti M, Middleton R, Mijović L, Mikenberg G, Mikestikova M, Mikuž M, Mildner H, Barr A, Milesi M, Milic A, Millar D, Miller D, Milov A, Milstead D, Mina R, Minaenko A, Miñano Moya M, Minashvili I, Barranco Navarro L, Mincer A, Mindur B, Mineev M, Minegishi Y, Ming Y, Mir L, Mirto A, Mistry K, Mitani T, Mitrevski J, Barreiro F, Mitsou V, Mittal M, Miucci A, Miyagawa P, Mizukami A, Mjörnmark J, Mkrtchyan T, Mlynarikova M, Moa T, Mochizuki K, Barreiro Guimarães da Costa J, Mogg P, Mohapatra S, Moles-Valls R, Mondragon M, Mönig K, Monk J, Monnier E, Montalbano A, Montejo Berlingen J, Montella M, Barsov S, Monticelli F, Monzani S, Morange N, Moreno D, Moreno Llácer M, Moreno Martinez C, Morettini P, Morgenstern M, Morgenstern S, Mori D, Bartoldus R, Morii M, Morinaga M, Morisbak V, Morley A, Mornacchi G, Morris A, Morvaj L, Moschovakos P, Moser B, Mosidze M, Bartolini G, Moskalets T, Moss H, Moss J, Motohashi K, Mountricha E, Moyse E, Muanza S, Mueller J, Mueller R, Muenstermann D, Barton A, Mullier G, Munoz Martinez J, Munoz Sanchez F, Murin P, Murray W, Murrone A, Muškinja M, Mwewa C, Myagkov A, Myers J, Bartos P, Myska M, Nachman B, Nackenhorst O, Nag AN, Nagai K, Nagano K, Nagasaka Y, Nagel M, Nagy E, Nairz A, Basalaev A, Nakahama Y, Nakamura K, Nakamura T, Nakano I, Nanjo H, Napolitano F, Naranjo Garcia R, Narayan R, Naryshkin I, Naumann T, Bassalat A, Navarro G, Neal H, Nechaeva P, Nechansky F, Neep T, Negri A, Negrini M, Nellist C, Nelson M, Nemecek S, Bates R, Nemethy P, Nessi M, Neubauer M, Neumann M, Newman P, Ng Y, Ng Y, Nguyen H, Nguyen Manh T, Nibigira E, Batista S, Nickerson R, Nicolaidou R, Nielsen D, Nielsen J, Nikiforou N, Nikolaenko V, Nikolic-Audit I, Nikolopoulos K, Nilsson P, Nindhito H, Batlamous S, Ninomiya Y, Nisati A, Nishu N, Nisius R, Nitsche I, Nitta T, Nobe T, Noguchi Y, Nomidis I, Nomura M, Batley J, Nordberg M, Norjoharuddeen N, Novak T, Novgorodova O, Novotny R, Nozka L, Ntekas K, Nurse E, Oakham F, Oberlack H, Batool B, Ocariz J, Ochi A, Ochoa I, Ochoa-Ricoux J, O’Connor K, Oda S, Odaka S, Oerdek S, Ogrodnik A, Oh A, Battaglia M, Oh S, Ohm C, Oide H, Ojeda M, Okawa H, Okazaki Y, Okumura Y, Okuyama T, Olariu A, Oleiro Seabra L, Bauce M, Olivares Pino S, Oliveira Damazio D, Oliver J, Olsson M, Olszewski A, Olszowska J, O’Neil D, Onofre A, Onogi K, Onyisi P, Bauer F, Oppen H, Oreglia M, Orellana G, Orestano D, Orlando N, Orr R, O’Shea V, Ospanov R, Otero y Garzon G, Otono H, Bauer K, Ott P, Ouchrif M, Ouellette J, Ould-Saada F, Ouraou A, Ouyang Q, Owen M, Owen R, Ozcan V, Ozturk N, Bawa H, Pacalt J, Pacey H, Pachal K, Pacheco Pages A, Padilla Aranda C, Pagan Griso S, Paganini M, Palacino G, Palazzo S, Palestini S, Beacham J, Palka M, Pallin D, Panagoulias I, Pandini C, Panduro Vazquez J, Pani P, Panizzo G, Paolozzi L, Papadatos C, Papageorgiou K, Beau T, Paramonov A, Paredes Hernandez D, Paredes Saenz S, Parida B, Park T, Parker A, Parker M, Parodi F, Parrish E, Parsons J, Beauchemin P, Parzefall U, Pascual Dominguez L, Pascuzzi V, Pasner J, Pasqualucci E, Passaggio S, Pastore F, Pasuwan P, Pataraia S, Pater J, Becherer F, Pathak A, Pauly T, Pearson B, Pedersen M, Pedraza Diaz L, Pedro R, Peiffer T, Peleganchuk S, Penc O, Peng H, Bechtle P, Peralva B, Perego M, Pereira Peixoto A, Perepelitsa D, Peri F, Perini L, Pernegger H, Perrella S, Peters K, Peters R, Beck H, Petersen B, Petersen T, Petit E, Petridis A, Petridou C, Petroff P, Petrov M, Petrucci F, Pettee M, Pettersson N, Beck H, Petukhova K, Peyaud A, Pezoa R, Pezzotti L, Pham T, Phillips F, Phillips P, Phipps M, Piacquadio G, Pianori E, Becker K, Picazio A, Pickles R, Piegaia R, Pietreanu D, Pilcher J, Pilkington A, Pinamonti M, Pinfold J, Pitt M, Pizzimento L, Becker M, Pleier MA, Pleskot V, Plotnikova E, Podberezko P, Poettgen R, Poggi R, Poggioli L, Pogrebnyak I, Pohl D, Pokharel I, Becot C, Polesello G, Poley A, Policicchio A, Polifka R, Polini A, Pollard C, Polychronakos V, Ponomarenko D, Pontecorvo L, Popa S, Beddall A, Popeneciu G, Portillo Quintero D, Pospisil S, Potamianos K, Potrap I, Potter C, Potti H, Poulsen T, Poveda J, Powell T, Beddall A, Pownall G, Pozo Astigarraga M, Pralavorio P, Prell S, Price D, Primavera M, Prince S, Proffitt M, Proklova N, Prokofiev K, Bednyakov V, Prokoshin F, Protopopescu S, Proudfoot J, Przybycien M, Pudzha D, Puri A, Puzo P, Qian J, Qin Y, Quadt A, Bedognetti M, Queitsch-Maitland M, Qureshi A, Rados P, Ragusa F, Rahal G, Raine J, Rajagopalan S, Ramirez Morales A, Ran K, Rashid T, Bee C, Raspopov S, Rauch D, Rauscher F, Rave S, Ravina B, Ravinovich I, Rawling J, Raymond M, Read A, Readioff N, Beermann T, Reale M, Rebuzzi D, Redelbach A, Redlinger G, Reeves K, Rehnisch L, Reichert J, Reikher D, Reiss A, Rej A, Begalli M, Rembser C, Renda M, Rescigno M, Resconi S, Resseguie E, Rettie S, Reynolds E, Rezanova O, Reznicek P, Ricci E, Begel M, Richter R, Richter S, Richter-Was E, Ricken O, Ridel M, Rieck P, Riegel C, Rifki O, Rijssenbeek M, Rimoldi A, Behera A, Rimoldi M, Rinaldi L, Ripellino G, Ristić B, Riu I, Rivera Vergara J, Rizatdinova F, Rizvi E, Rizzi C, Roberts R, Behr J, Robertson S, Robin M, Robinson D, Robinson J, Robles Gajardo C, Robson A, Rocco E, Roda C, Rodriguez Bosca S, Rodriguez Perez A, Beisiegel F, Rodriguez Rodriguez D, Rodríguez Vera A, Roe S, Røhne O, Röhrig R, Roland C, Roloff J, Romaniouk A, Romano M, Rompotis N, Bell A, Ronzani M, Roos L, Rosati S, Rosbach K, Rosin G, Rosser B, Rossi E, Rossi E, Rossi E, Rossi L, Bella G, Rossini L, Rosten R, Rotaru M, Rothberg J, Rousseau D, Rovelli G, Roy A, Roy D, Rozanov A, Rozen Y, Bellagamba L, Ruan X, Rubbo F, Rühr F, Ruiz-Martinez A, Rummler A, Rurikova Z, Rusakovich N, Russell H, Rustige L, Rutherfoord J, Bellerive A, Rüttinger E, Rybar M, Rybkin G, Rye E, Ryzhov A, Rzehorz G, Sabatini P, Sabato G, Sacerdoti S, Sadrozinski HW, Bellos P, Sadykov R, Safai Tehrani F, Safarzadeh Samani B, Saha P, Saha S, Sahinsoy M, Sahu A, Saimpert M, Saito M, Saito T, Beloborodov K, Sakamoto H, Sakharov A, Salamani D, Salamanna G, Salazar Loyola J, Sales De Bruin P, Salnikov A, Salt J, Salvatore D, Salvatore F, Belotskiy K, Salvucci A, Salzburger A, Samarati J, Sammel D, Sampsonidis D, Sampsonidou D, Sánchez J, Sanchez Pineda A, Sandaker H, Sander C, Belyaev N, Sanderswood I, Sandhoff M, Sandoval C, Sankey D, Sannino M, Sano Y, Sansoni A, Santoni C, Santos H, Santpur S, Benchekroun D, Santra A, Sapronov A, Saraiva J, Sasaki O, Sato K, Sauvan E, Savard P, Savic N, Sawada R, Sawyer C, Benekos N, Sawyer L, Sbarra C, Sbrizzi A, Scanlon T, Schaarschmidt J, Schacht P, Schachtner B, Schaefer D, Schaefer L, Schaeffer J, Benhammou Y, Schaepe S, Schäfer U, Schaffer A, Schaile D, Schamberger R, Scharmberg N, Schegelsky V, Scheirich D, Schenck F, Schernau M, Benjamin D, Schiavi C, Schier S, Schildgen L, Schillaci Z, Schioppa E, Schioppa M, Schleicher K, Schlenker S, Schmidt-Sommerfeld K, Schmieden K, Benoit M, Schmitt C, Schmitt S, Schmitz S, Schmoeckel J, Schnoor U, Schoeffel L, Schoening A, Scholer P, Schopf E, Schott M, Bensinger J, Schouwenberg J, Schovancova J, Schramm S, Schroeder F, Schulte A, Schultz-Coulon HC, Schumacher M, Schumm B, Schune P, Schwartzman A, Bentvelsen S, Schwarz T, Schwemling P, Schwienhorst R, Sciandra A, Sciolla G, Scodeggio M, Scornajenghi M, Scuri F, Scutti F, Scyboz L, Beresford L, Sebastiani C, Seema P, Seidel S, Seiden A, Seiss T, Seixas J, Sekhniaidze G, Sekhon K, Sekula S, Semprini-Cesari N, Beretta M, Sen S, Senkin S, Serfon C, Serin L, Serkin L, Sessa M, Severini H, Šfiligoj T, Sforza F, Sfyrla A, Berge D, Shabalina E, Shahinian J, Shaikh N, Shaked Renous D, Shan L, Shang R, Shank J, Shapiro M, Sharma A, Sharma A, Bergeaas Kuutmann E, Shatalov P, Shaw K, Shaw S, Shcherbakova A, Shen Y, Sherafati N, Sherman A, Sherwood P, Shi L, Shimizu S, Berger N, Shimmin C, Shimogama Y, Shimojima M, Shipsey I, Shirabe S, Shiyakova M, Shlomi J, Shmeleva A, Shochet M, Shojaii J, Bergmann B, Shope D, Shrestha S, Shrif E, Shulga E, Sicho P, Sickles A, Sidebo P, Sideras Haddad E, Sidiropoulou O, Sidoti A, Bergsten L, Siegert F, Sijacki D, Silva M, Silva Oliveira M, Silverstein S, Simion S, Simioni E, Simoniello R, Simsek S, Sinervo P, Beringer J, Sinetckii V, Sinev N, Sioli M, Siral I, Sivoklokov S, Sjölin J, Skorda E, Skubic P, Slawinska M, Sliwa K, Berlendis S, Slovak R, Smakhtin V, Smart B, Smiesko J, Smirnov N, Smirnov S, Smirnov Y, Smirnova L, Smirnova O, Smith J, Bernard N, Smizanska M, Smolek K, Smykiewicz A, Snesarev A, Snoek H, Snyder I, Snyder S, Sobie R, Soffa A, Soffer A, Bernardi G, Søgaard A, Sohns F, Solans Sanchez C, Soldatov E, Soldevila U, Solodkov A, Soloshenko A, Solovyanov O, Solovyev V, Sommer P, Bernius C, Son H, Song W, Song W, Sopczak A, Sopkova F, Sotiropoulou C, Sottocornola S, Soualah R, Soukharev A, South D, Bernlochner F, Spagnolo S, Spalla M, Spangenberg M, Spanò F, Sperlich D, Spieker T, Spighi R, Spigo G, Spina M, Spiteri D, Berry T, Spousta M, Stabile A, Stamas B, Stamen R, Stamenkovic M, Stanecka E, Stanek R, Stanislaus B, Stanitzki M, Stankaityte M, Berta P, Stapf B, Starchenko E, Stark G, Stark J, Stark S, Staroba P, Starovoitov P, Stärz S, Staszewski R, Stavropoulos G, Bertella C, Stegler M, Steinberg P, Steinhebel A, Stelzer B, Stelzer H, Stelzer-Chilton O, Stenzel H, Stevenson T, Stewart G, Stockton M, Bertram I, Stoicea G, Stolarski M, Stolte P, Stonjek S, Straessner A, Strandberg J, Strandberg S, Strauss M, Strizenec P, Ströhmer R, Besjes G, Strom D, Stroynowski R, Strubig A, Stucci S, Stugu B, Stupak J, Styles N, Su D, Suchek S, Sulin V, Bessidskaia Bylund O, Sullivan M, Sultan D, Sultansoy S, Sumida T, Sun S, Sun X, Suruliz K, Suster C, Sutton M, Suzuki S, Besson N, Svatos M, Swiatlowski M, Swift S, Swirski T, Sydorenko A, Sykora I, Sykora M, Sykora T, Ta D, Tackmann K, Bethani A, Taenzer J, Taffard A, Tafirout R, Takai H, Takashima R, Takeda K, Takeshita T, Takeva E, Takubo Y, Talby M, Bethke S, Talyshev A, Tamir N, Tanaka J, Tanaka M, Tanaka R, Tapia Araya S, Tapprogge S, Tarek Abouelfadl Mohamed A, Tarem S, Tarna G, Betti A, Tartarelli G, Tas P, Tasevsky M, Tashiro T, Tassi E, Tavares Delgado A, Tayalati Y, Taylor A, Taylor G, Taylor W, Bevan A, Tee A, Teixeira De Lima R, Teixeira-Dias P, Ten Kate H, Teoh J, Terada S, Terashi K, Terron J, Terzo S, Testa M, Beyer J, Teuscher R, Thais S, Theveneaux-Pelzer T, Thiele F, Thomas D, Thomas J, Thomas J, Thompson A, Thompson P, Thomsen L, Bi R, Thomson E, Thorpe E, Tian Y, Ticse Torres R, Tikhomirov V, Tikhonov Y, Timoshenko S, Tipton P, Tisserant S, Todome K, Bianchi R, Todorova-Nova S, Todt S, Tojo J, Tokár S, Tokushuku K, Tolley E, Tomiwa K, Tomoto M, Tompkins L, Tong B, Biebel O, Tornambe P, Torrence E, Torres H, Torró Pastor E, Tosciri C, Toth J, Tovey D, Traeet A, Treado C, Trefzger T, Biedermann D, Tresoldi F, Tricoli A, Trigger I, Trincaz-Duvoid S, Trischuk W, Trocmé B, Trofymov A, Troncon C, Trovatelli M, Trovato F, Bielski R, Truong L, Trzebinski M, Trzupek A, Tsai F, Tseng JL, Tsiareshka P, Tsirigotis A, Tsirintanis N, Tsiskaridze V, Tskhadadze E, Bierwagen K, Tsopoulou M, Tsukerman I, Tsulaia V, Tsuno S, Tsybychev D, Tu Y, Tudorache A, Tudorache V, Tulbure T, Tuna A, Biesuz N, Turchikhin S, Turgeman D, Turk Cakir I, Turner R, Turra R, Tuts P, Tzamarias S, Tzovara E, Ucchielli G, Uchida K, Biglietti M, Ueda I, Ughetto M, Ukegawa F, Unal G, Undrus A, Unel G, Ungaro F, Unno Y, Uno K, Urban J, Billoud T, Urquijo P, Usai G, Usui J, Uysal Z, Vacavant L, Vacek V, Vachon B, Vadla K, Vaidya A, Valderanis C, Bindi M, Valdes Santurio E, Valente M, Valentinetti S, Valero A, Valéry L, Vallance R, Vallier A, Valls Ferrer J, Van Daalen T, Van Gemmeren P, Bingul A, Van Vulpen I, Vanadia M, Vandelli W, Vaniachine A, Vannicola D, Vari R, Varnes E, Varni C, Varol T, Varouchas D, Bini C, Varvell K, Vasile M, Vasquez G, Vasquez J, Vazeille F, Vazquez Furelos D, Vazquez Schroeder T, Veatch J, Vecchio V, Veen M, Biondi S, Veloce L, Veloso F, Veneziano S, Ventura A, Venturi N, Verbytskyi A, Vercesi V, Verducci M, Vergel Infante C, Vergis C, Birman M, Verkerke W, Vermeulen A, Vermeulen J, Vetterli M, Viaux Maira N, Vicente Barreto Pinto M, Vickey T, Vickey Boeriu O, Viehhauser G, Vigani L, Bisanz T, Villa M, Villaplana Perez M, Vilucchi E, Vincter M, Vinogradov V, Vishwakarma A, Vittori C, Vivarelli I, Vogel M, Vokac P, Biswal J, von Buddenbrock S, Von Toerne E, Vorobel V, Vorobev K, Vos M, Vossebeld J, Vozak M, Vranjes N, Vranjes Milosavljevic M, Vrba V, Bitadze A, Vreeswijk M, Vuillermet R, Vukotic I, Wagner P, Wagner W, Wagner-Kuhr J, Wahdan S, Wahlberg H, Wakamiya K, Walbrecht V, Bittrich C, Walder J, Walker R, Walker S, Walkowiak W, Wallangen V, Wang A, Wang C, Wang C, Wang F, Wang H, Bjørke K, Wang H, Wang J, Wang J, Wang P, Wang Q, Wang RJ, Wang R, Wang R, Wang S, Wang W, Black K, Wang W, Wang W, Wang Y, Wang Z, Wanotayaroj C, Warburton A, Ward C, Wardrope D, Warrack N, Washbrook A, Blazek T, Watson A, Watson M, Watts G, Waugh B, Webb A, Webb S, Weber C, Weber M, Weber S, Weber S, Bloch I, Weidberg A, Weingarten J, Weirich M, Weiser C, Wells P, Wenaus T, Wengler T, Wenig S, Wermes N, Werner M, Blocker C, Wessels M, Weston T, Whalen K, Whallon N, Wharton A, White A, White A, White M, Whiteson D, Whitmore B, Blue A, Wiedenmann W, Wielers M, Wieseotte N, Wiglesworth C, Wiik-Fuchs L, Wilk F, Wilkens H, Wilkins L, Williams H, Williams S, Blumenschein U, Willis C, Willocq S, Wilson J, Wingerter-Seez I, Winkels E, Winklmeier F, Winston O, Winter B, Wittgen M, Wobisch M, Bobbink G, Wolf A, Wolf T, Wolff R, Wölker R, Wollrath J, Wolter M, Wolters H, Wong V, Woods N, Worm S, Bobrovnikov V, Wosiek B, Woźniak K, Wraight K, Wu S, Wu X, Wu Y, Wyatt T, Wynne B, Xella S, Xi Z, Bocchetta S, Xia L, Xu D, Xu H, Xu L, Xu T, Xu W, Xu Z, Xu Z, Yabsley B, Yacoob S, Bocci A, Yajima K, Yallup D, Yamaguchi D, Yamaguchi Y, Yamamoto A, Yamane F, Yamatani M, Yamazaki T, Yamazaki Y, Yan Z, Boerner D, Yang H, Yang H, Yang S, Yang X, Yang Y, Yao WM, Yap Y, Yasu Y, Yatsenko E, Ye J, Bogavac D, Ye S, Yeletskikh I, Yexley M, Yigitbasi E, Yorita K, Yoshihara K, Young C, Young C, Yu J, Yuan R, Bogdanchikov A, Yue X, Yuen S, Zabinski B, Zacharis G, Zaffaroni E, Zahreddine J, Zaitsev A, Zakareishvili T, Zakharchuk N, Zambito S, Bohm C, Zanzi D, Zaripovas D, Zeißner S, Zeitnitz C, Zemaityte G, Zeng J, Zenin O, Ženiš T, Zerwas D, Zgubič M, Boisvert V, Zhang D, Zhang F, Zhang G, Zhang G, Zhang H, Zhang J, Zhang L, Zhang L, Zhang M, Zhang R, Bokan P, Zhang R, Zhang X, Zhang Y, Zhang Z, Zhang Z, Zhao P, Zhao Y, Zhao Z, Zhemchugov A, Zheng Z, Bold T, Zhong D, Zhou B, Zhou C, Zhou M, Zhou M, Zhou N, Zhou Y, Zhu C, Zhu H, Zhu H, Boldyrev A, Zhu J, Zhu Y, Zhuang X, Zhukov K, Zhulanov V, Zieminska D, Zimine N, Zimmermann S, Zinonos Z, Ziolkowski M, Bolz A, Živković L, Zobernig G, Zoccoli A, Zoch K, Zorbas T, Zou R, Zwalinski L, Bomben M, Bona M, Bonilla J, Boonekamp M, Borecka-Bielska H, Borisov A, Borissov G, Bortfeldt J, Bortoletto D, Bortolotto V, Boscherini D, Bosman M, Bossio Sola J, Bouaouda K, Boudreau J, Bouhova-Thacker E, Boumediene D, Boutle S, Boveia A, Boyd J, Boye D, Boyko I, Bozson A, Bracinik J, Brahimi N, Brandt G, Brandt O, Braren F, Brau B, Brau J, Breaden Madden W, Brendlinger K, Brenner L, Brenner R, Bressler S, Brickwedde B, Briglin D, Britton D, Britzger D, Brock I, Brock R, Brooijmans G, Brooks W, Brost E, Broughton J, Bruckman de Renstrom P, Bruncko D, Bruni A, Bruni G, Bruni L, Bruno S, Brunt B, Bruschi M, Bruscino N, Bryant P, Bryngemark L, Buanes T, Buat Q, Buchholz P, Buckley A, Budagov I, Bugge M, Bührer F, Bulekov O, Burch T, Burdin S, Burgard C, Burger A, Burghgrave B, Burr J, Burzynski J, Büscher V, Buschmann E, Bussey P, Butler J, Buttar C, Butterworth J, Butti P, Buttinger W, Buzatu A, Buzykaev A, Cabras G, Cabrera Urbán S, Caforio D, Cai H, Cairo V, Cakir O, Calace N, Calafiura P, Calandri A, Calderini G, Calfayan P, Callea G, Caloba L, Calvente Lopez S, Calvet D, Calvet S, Calvet T, Calvetti M, Camacho Toro R, Camarda S, Camarero Munoz D, Camarri P, Cameron D, Caminal Armadans R, Camincher C, Campana S, Campanelli M, Camplani A, Campoverde A, Canale V, Canesse A, Cano Bret M, Cantero J, Cao T, Cao Y, Capeans Garrido M, Capua M, Cardarelli R, Cardillo F, Carducci G, Carli I, Carli T, Carlino G, Carlson B, Carminati L, Carney R, Caron S, Carquin E, Carrá S, Carter J, Casado M, Casha A, Casper D, Castelijn R, Castillo F, Castillo Gimenez V, Castro N, Catinaccio A, Catmore J, Cattai A, Caudron J, Cavaliere V, Cavallaro E, Cavalli-Sforza M, Cavasinni V, Celebi E, Ceradini F, Cerda Alberich L, Cerny K, Cerqueira A, Cerri A, Cerrito L, Cerutti F, Cervelli A, Cetin S, Chadi Z, Chakraborty D, Chan S, Chan W, Chan W, Chapman J, Chargeishvili B, Charlton D, Charman T, Chau C, Che S, Chegwidden A, Chekanov S, Chekulaev S, Chelkov G, Chelstowska M, Chen B, Chen C, Chen C, Chen H, Chen J, Chen J, Chen S, Chen S, Chen X, Chen Y, Chen YH, Cheng H, Cheng H, Cheplakov A, Cheremushkina E, Cherkaoui El Moursli R, Cheu E, Cheung K, Chevalérias T, Chevalier L, Chiarella V, Chiarelli G, Chiodini G, Chisholm A, Chitan A, Chiu I, Chiu Y, Chizhov M, Choi K, Chomont A, Chouridou S, Chow Y, Chu M, Chu X, Chudoba J, Chuinard A, Chwastowski J, Chytka L, Ciesla K, Cinca D, Cindro V, Cioară I, Ciocio A, Cirotto F, Citron Z, Citterio M, Ciubotaru D, Ciungu B, Clark A, Clark M, Clark P, Clement C, Coadou Y, Cobal M, Coccaro A, Cochran J, Cohen H, Coimbra A, Colasurdo L, Cole B, Colijn A, Collot J, Conde Muiño P, Coniavitis E, Connell S, Connelly I, Constantinescu S, Conventi F, Cooper-Sarkar A, Cormier F, Cormier K, Corpe L, Corradi M, Corrigan E, Corriveau F, Costa M, Costanza F, Costanzo D, Cowan G, Cowley J, Crane J, Cranmer K, Crawley S, Creager R, Crépé-Renaudin S, Crescioli F, Cristinziani M, Croft V, Crosetti G, Cueto A, Cuhadar Donszelmann T, Cukierman A, Czekierda S, Czodrowski P, Da Cunha Sargedas De Sousa M, Da Fonseca Pinto J, Da Via C, Dabrowski W, Dado T, Dahbi S, Dai T, Dallapiccola C, Dam M, D’amen G, D’Amico V, Damp J, Dandoy J, Daneri M, Dang N, Dann N, Danninger M, Dao V, Darbo G, Dartsi O, Dattagupta A, Daubney T, D’Auria S, Davey W, David C, Davidek T, Davis D, Dawson I, De K, De Asmundis R, De Beurs M, De Castro S, De Cecco S, De Groot N, de Jong P, De la Torre H, De Maria A, De Pedis D, De Salvo A, De Sanctis U, De Santis M, De Santo A, De Vasconcelos Corga K, De Vivie De Regie J, Debenedetti C, Dedovich D, Deiana A, Del Gaudio M, Del Peso J, Delabat Diaz Y, Delgove D, Deliot F, Delitzsch C, Della Pietra M, Della Volpe D, Dell’Acqua A, Dell’Asta L, Delmastro M, Delporte C, Delsart P, DeMarco D, Demers S, Demichev M, Demontigny G, Denisov S, Denysiuk D, D’Eramo L, Derendarz D, Derkaoui J, Derue F, Dervan P, Desch K, Deterre C, Dette K, Deutsch C, Devesa M, Deviveiros P, Dewhurst A, Dhaliwal S, Di Bello F, Di Ciaccio A, Di Ciaccio L, Di Clemente W, Di Donato C, Di Girolamo A, Di Gregorio G, Di Micco B, Di Nardo R, Di Petrillo K, Di Sipio R, Di Valentino D, Diaconu C, Dias F, Dias Do Vale T, Diaz M, Dickinson J, Diehl E, Dietrich J, Díez Cornell S, Dimitrievska A, Ding W, Dingfelder J, Dittus F, Djama F, Djobava T, Djuvsland J, Do Vale M, Dobre M, Dodsworth D, Doglioni C, Dolejsi J, Dolezal Z, Donadelli M, Dong B, Donini J, D’onofrio A, D’Onofrio M, Dopke J, Doria A, Dova M, Doyle A, Drechsler E, Dreyer E, Dreyer T, Drobac A, Duan Y, Dubinin F, Dubovsky M, Dubreuil A, Duchovni E, Duckeck G, Ducourthial A, Ducu O, Duda D, Dudarev A, Dudder A, Duffield E, Duflot L, Dührssen M, Dülsen C, Dumancic M, Dumitriu A, Duncan A, Dunford M, Duperrin A, Duran Yildiz H, Düren M, Durglishvili A, Duschinger D, Dutta B, Duvnjak D, Dyckes G, Dyndal M, Dysch S, Dziedzic B, Ecker K, Edgar R, Eifert T, Eigen G, Einsweiler K, Ekelof T, El Jarrari H, El Kacimi M, El Kosseifi R, Ellajosyula V, Ellert M, Ellinghaus F, Elliot A, Ellis N, Elmsheuser J, Elsing M, Emeliyanov D, Emerman A, Enari Y, Epland M, Erdmann J, Ereditato A, Errenst M, Escalier M, Escobar C, Estrada Pastor O, Etzion E, Evans H, Ezhilov A, Fabbri F, Fabbri L, Fabiani V, Facini G, Faisca Rodrigues Pereira R, Fakhrutdinov R, Falciano S, Falke P, Falke S, Faltova J, Fang Y, Fang Y, Fanourakis G, Fanti M, Faraj M, Farbin A, Farilla A, Farina E, Farooque T, Farrell S, Farrington S, Farthouat P, Fassi F, Fassnacht P, Fassouliotis D, Faucci Giannelli M, Fawcett W, Fayard L, Fedin O, Fedorko W, Feickert M, Feigl S, Feligioni L, Fell A, Feng C, Feng E, Feng M, Fenton M, Fenyuk A, Ferrando J, Ferrante A, Ferrari A, Ferrari P, Ferrari R, Ferreira de Lima D, Ferrer A, Ferrere D, Ferretti C, Fiedler F, Filipčič A, Filthaut F, Finelli K, Fiolhais M, Fiorini L, Fischer F, Fisher W, Fleck I, Fleischmann P, Fletcher R, Flick T, Flierl B, Flores L, Flores Castillo L, Follega F, Fomin N, Foo J, Forcolin G, Formica A, Förster F, Forti A, Foster A, Foti M, Fournier D, Fox H, Francavilla P, Francescato S, Franchini M, Franchino S, Francis D, Franconi L, Franklin M, Fray A, Freund B, Freund W, Freundlich E, Frizzell D, Froidevaux D, Frost J, Fukunaga C, Fullana Torregrosa E, Fumagalli E, Fusayasu T, Fuster J, Gabrielli A, Gabrielli A, Gach G, Gadatsch S, Gadow P, Gagliardi G, Gagnon L, Galea C, Galhardo B, Gallardo G, Gallas E, Gallop B, Galster G, Gamboa Goni R, Gan K, Ganguly S, Gao J, Gao Y, Gao Y, García C, García Navarro J, García Pascual J, Garcia-Argos C, Garcia-Sciveres M, Gardner R, Garelli N, Gargiulo S, Garonne V, Gaudiello A, Gaudio G, Gavrilenko I, Gavrilyuk A, Gay C, Gaycken G, Gazis E, Geanta A, Gee C, Geisen J, Geisen M, Geisler M, Gemme C, Genest M, Geng C, Gentile S, George S, Geralis T, Gerlach L, Gessinger-Befurt P, Gessner G, Ghasemi S, Ghasemi Bostanabad M, Ghosh A, Ghosh A, Giacobbe B, Giagu S, Giangiacomi N, Giannetti P, Giannini A, Gibson S, Gignac M, Gillberg D, Gilles G, Gingrich D, Giordani M, Giorgi F, Giraud P, Giugliarelli G, Giugni D, Giuli F, Gkaitatzis S, Gkialas I, Gkougkousis E, Gkountoumis P, Gladilin L, Glasman C, Glatzer J, Glaysher P, Glazov A, Goblirsch-Kolb M, Goldfarb S, Golling T, Golubkov D, Gomes A, Goncalves Gama R, Gonçalo R, Gonella G, Gonella L, Gongadze A, Gonnella F, Gonski J, González de la Hoz S, Gonzalez-Sevilla S, Gonzalvo Rodriguez G, Goossens L, Gorbounov P, Gordon H, Gorini B, Gorini E, Gorišek A, Goshaw A, Gostkin M, Gottardo C, Gouighri M, Goujdami D, Goussiou A, Govender N, Goy C, Gozani E, Grabowska-Bold I, Graham E, Gramling J, Gramstad E, Grancagnolo S, Grandi M, Gratchev V, Gravila P, Gravili F, Gray C, Gray H, Grefe C, Gregersen K, Gregor I, Grenier P, Grevtsov K, Grieco C, Grieser N, Griffiths J, Grillo A, Grimm K, Grinstein S, Grivaz JF, Groh S, Gross E, Grosse-Knetter J, Grout Z, Grud C, Grummer A, Guan L, Guan W, Guenther J, Guerguichon A, Guerrero Rojas J, Guescini F, Guest D, Gugel R, Guillemin T, Guindon S, Gul U, Guo J, Guo W, Guo Y, Guo Z, Gupta R, Gurbuz S, Gustavino G, Gutierrez P, Gutschow C, Guyot C, Gwenlan C, Gwilliam C, Haas A, Haber C, Hadavand H. Search for heavy neutral Higgs bosons produced in association with
b
-quarks and decaying into
b
-quarks at
s=13 TeV
with the ATLAS detector. Int J Clin Exp Med 2020. [DOI: 10.1103/physrevd.102.032004] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
43
|
Kondo T, Tanaka M, Yamataka K, Kikuchi Y, Mihara K, Shito M. Laparoscopic reversal of Hartmann's procedure using the reverse transrectal stapling technique. Tech Coloproctol 2020; 24:1309-1310. [PMID: 32683597 DOI: 10.1007/s10151-020-02302-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/17/2020] [Accepted: 07/12/2020] [Indexed: 10/23/2022]
|
44
|
Tsukada T, Tanaka M, Miyazaki Y, Nishiura Y, Yamashita T, Kishikawa M. A case of unilateral shoulder joint hydrarthrosis with wild-type amyloidogenic transthyretin amyloidosis. Mod Rheumatol Case Rep 2020; 4:312-317. [PMID: 33087007 DOI: 10.1080/24725625.2020.1751380] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2019] [Accepted: 03/31/2020] [Indexed: 06/11/2023]
Abstract
Wild-type amyloidogenic transthyretin (ATTR) amyloidosis, known as systemic senile amyloidosis (SSA), is an age-related nonhereditary amyloidosis, which is known to cause cardiomyopathy and carpal tunnel syndrome (CTS). Herein, we report a case of unilateral hydrarthrosis with arthritis of the right shoulder joint in an 82-year-old Japanese housewife who has a seven year history of polyneuropathy due to an unknown aetiology. At first, her joint pain was thought to be caused by overuse of her right upper arm. Despite treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and repeated arthrocentesis, her symptoms did not improve. She then visited our hospital, where magnetic resonance imaging (MRI) of her right shoulder suggested synovitis and hydrarthrosis. She also had an arthroscopic synovectomy of the right shoulder joint. The pathological testing revealed a diagnosis of non-specific arthritis with amyloidosis. After further pathological examination, wild-type ATTR was identified and she was diagnosed with senile amyloidosis.
Collapse
|
45
|
Portelli F, Galli F, Cattaneo L, Cossa M, De Giorgi V, Forte G, Fraternali Orcioni G, Gianatti A, Indini A, Labianca A, Maurichi A, Merelli B, Montesco MC, Occelli M, Patuzzo R, Piazzalunga D, Pigozzo J, Quaglino P, Ribero S, Salvatori R, Saraggi D, Sena P, Senetta R, Valeri B, Tanaka M, Fukayama M, Palmieri G, Mandalà M, Massi D. The prognostic impact of the extent of ulceration in patients with clinical stage I-II melanoma: a multicentre study of the Italian Melanoma Intergroup (IMI). Br J Dermatol 2020; 184:281-288. [PMID: 32282932 DOI: 10.1111/bjd.19120] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/03/2020] [Indexed: 12/15/2022]
Abstract
BACKGROUND The presence of ulceration has been recognized as an adverse prognostic factor in primary cutaneous melanoma (PCM). OBJECTIVES To investigate whether the extent of ulceration (EoU) predicts relapse-free survival (RFS) and overall survival (OS) in PCM. MATERIALS AND METHODS We retrieved data for 477 patients with ulcerated PCM from databases of the Italian Melanoma Intergroup. Univariate and multivariable Cox proportional hazard models were used to assess the independent prognostic impact of EoU. RESULTS A significant interaction emerged between Breslow thickness (BT) and EoU, considering both RFS (P < 0·0001) and OS (P = 0·0006). At multivariable analysis, a significant negative impact of EoU on RFS [hazard ratio (HR) (1-mm increase) 1·26, 95% confidence interval (CI) 1·08-1·48, P = 0·0047] and OS [HR (1-mm increase) 1·25, 95% CI 1·05-1·48, P = 0·0120] was found in patients with BT ≤ 2 mm, after adjusting for BT, age, tumour-infiltrating lymphocytes, sentinel lymph node status and mitotic rate. No impact of EoU was found in patients with 2·01-4 mm and > 4 mm BT. CONCLUSIONS This study demonstrates that EoU has an independent prognostic impact in PCM and should be recorded as a required element in pathology reports.
Collapse
|
46
|
Aad G, Abbott B, Abbott DC, Abed Abud A, Abeling K, Abhayasinghe DK, Abidi SH, AbouZeid OS, Abraham NL, Abramowicz H, Abreu H, Abulaiti Y, Acharya BS, Achkar B, Adachi S, Adam L, Adam Bourdarios C, Adamczyk L, Adamek L, Adelman J, Adersberger M, Adiguzel A, Adorni S, Adye T, Affolder AA, Afik Y, Agapopoulou C, Agaras MN, Aggarwal A, Agheorghiesei C, Aguilar-Saavedra JA, Ahmadov F, Ahmed WS, Ai X, Aielli G, Akatsuka S, Åkesson TPA, Akilli E, Akimov AV, Al Khoury K, Alberghi GL, Albert J, Alconada Verzini MJ, Alderweireldt S, Aleksa M, Aleksandrov IN, Alexa C, Alexopoulos T, Alfonsi A, Alfonsi F, Alhroob M, Ali B, Aliev M, Alimonti G, Alkire SP, Allaire C, Allbrooke BMM, Allen BW, Allport PP, Aloisio A, Alonso A, Alonso F, Alpigiani C, Alshehri AA, Alvarez Estevez M, Álvarez Piqueras D, Alviggi MG, Amaral Coutinho Y, Ambler A, Ambroz L, Amelung C, Amidei D, Amor Dos Santos SP, Amoroso S, Amrouche CS, An F, Anastopoulos C, Andari N, Andeen T, Anders CF, Anders JK, Andreazza A, Andrei V, Anelli CR, Angelidakis S, Angerami A, Anisenkov AV, Annovi A, Antel C, Anthony MT, Antipov E, Antonelli M, Antrim DJA, Anulli F, Aoki M, Aparisi Pozo JA, Aperio Bella L, Araque JP, Araujo Ferraz V, Araujo Pereira R, Arcangeletti C, Arce ATH, Arduh FA, Arguin JF, Argyropoulos S, Arling JH, Armbruster AJ, Armstrong A, Arnaez O, Arnold H, Arrubarrena Tame ZP, Artoni G, Artz S, Asai S, Asbah N, Asimakopoulou EM, Asquith L, Assahsah J, Assamagan K, Astalos R, Atkin RJ, Atkinson M, Atlay NB, Atmani H, Augsten K, Avolio G, Avramidou R, Ayoub MK, Azoulay AM, Azuelos G, Bachacou H, Bachas K, Backes M, Backman F, Bagnaia P, Bahmani M, Bahrasemani H, Bailey AJ, Bailey VR, Baines JT, Bajic M, Bakalis C, Baker OK, Bakker PJ, Bakshi Gupta D, Balaji S, Baldin EM, Balek P, Balli F, Balunas WK, Balz J, Banas E, Bandyopadhyay A, Banerjee S, Bannoura AAE, Barak L, Barbe WM, Barberio EL, Barberis D, Barbero M, Barbour G, Barillari T, Barisits MS, Barkeloo J, Barklow T, Barnea R, Barnes SL, Barnett BM, Barnett RM, Barnovska-Blenessy Z, Baroncelli A, Barone G, Barr AJ, Barranco Navarro L, Barreiro F, Barreiro Guimarães da Costa J, Barsov S, Bartoldus R, Bartolini G, Barton AE, Bartos P, Basalaev A, Basan A, Bassalat A, Basso MJ, Bates RL, Batlamous S, Batley JR, Batool B, Battaglia M, Bauce M, Bauer F, Bauer KT, Bawa HS, Beacham JB, Beau T, Beauchemin PH, Becherer F, Bechtle P, Beck HC, Beck HP, Becker K, Becker M, Becot C, Beddall A, Beddall AJ, Bednyakov VA, Bedognetti M, Bee CP, Beermann TA, Begalli M, Begel M, Behera A, Behr JK, Beisiegel F, Bell AS, Bella G, Bellagamba L, Bellerive A, Bellos P, Beloborodov K, Belotskiy K, Belyaev NL, Benchekroun D, Benekos N, Benhammou Y, Benjamin DP, Benoit M, Bensinger JR, Bentvelsen S, Beresford L, Beretta M, Berge D, Bergeaas Kuutmann E, Berger N, Bergmann B, Bergsten LJ, Beringer J, Berlendis S, Bernardi G, Bernius C, Bernlochner FU, Berry T, Berta P, Bertella C, Bertram IA, Bessidskaia Bylund O, Besson N, Bethani A, Bethke S, Betti A, Bevan AJ, Beyer J, Bhattacharya DS, Bhattarai P, Bi R, Bianchi RM, Biebel O, Biedermann D, Bielski R, Bierwagen K, Biesuz NV, Biglietti M, Billoud TRV, Bindi M, Bingul A, Bini C, Biondi S, Birman M, Bisanz T, Biswal JP, Biswas D, Bitadze A, Bittrich C, Bjørke K, Black KM, Blazek T, Bloch I, Blocker C, Blue A, Blumenschein U, Bobbink GJ, Bobrovnikov VS, Bocchetta SS, Bocci A, Boerner D, Bogavac D, Bogdanchikov AG, Bohm C, Boisvert V, Bokan P, Bold T, Boldyrev AS, Bolz AE, Bomben M, Bona M, Bonilla JS, Boonekamp M, Booth CD, Borecka-Bielska HM, Borisov A, Borissov G, Bortfeldt J, Bortoletto D, Boscherini D, Bosman M, Bossio Sola JD, Bouaouda K, Boudreau J, Bouhova-Thacker EV, Boumediene D, Boutle SK, Boveia A, Boyd J, Boye D, Boyko IR, Bozson AJ, Bracinik J, Brahimi N, Brandt G, Brandt O, Braren F, Brau B, Brau JE, Breaden Madden WD, Brendlinger K, Brenner L, Brenner R, Bressler S, Brickwedde B, Briglin DL, Britton D, Britzger D, Brock I, Brock R, Brooijmans G, Brooks WK, Brost E, Broughton JH, Bruckman de Renstrom PA, Bruncko D, Bruni A, Bruni G, Bruni LS, Bruno S, Bruschi M, Bruscino N, Bryant P, Bryngemark L, Buanes T, Buat Q, Buchholz P, Buckley AG, Budagov IA, Bugge MK, Bührer F, Bulekov O, Burch TJ, Burdin S, Burgard CD, Burger AM, Burghgrave B, Burr JTP, Burton CD, Burzynski JC, Büscher V, Buschmann E, Bussey PJ, Butler JM, Buttar CM, Butterworth JM, Butti P, Buttinger W, Buxo Vazquez CJ, Buzatu A, Buzykaev AR, Cabras G, Cabrera Urbán S, Caforio D, Cai H, Cairo VMM, Cakir O, Calace N, Calafiura P, Calandri A, Calderini G, Calfayan P, Callea G, Caloba LP, Caltabiano A, Calvente Lopez S, Calvet D, Calvet S, Calvet TP, Calvetti M, Camacho Toro R, Camarda S, Camarero Munoz D, Camarri P, Cameron D, Caminal Armadans R, Camincher C, Campana S, Campanelli M, Camplani A, Campoverde A, Canale V, Canesse A, Cano Bret M, Cantero J, Cao T, Cao Y, Capeans Garrido MDM, Capua M, Cardarelli R, Cardillo F, Carducci G, Carli I, Carli T, Carlino G, Carlson BT, Carminati L, Carney RMD, Caron S, Carquin E, Carrá S, Carter JWS, Casado MP, Casha AF, Casper DW, Castelijn R, Castillo FL, Castillo Gimenez V, Castro NF, Catinaccio A, Catmore JR, Cattai A, Cavaliere V, Cavallaro E, Cavalli-Sforza M, Cavasinni V, Celebi E, Ceradini F, Cerda Alberich L, Cerny K, Cerqueira AS, Cerri A, Cerrito L, Cerutti F, Cervelli A, Cetin SA, Chadi Z, Chakraborty D, Chan WS, Chan WY, Chapman JD, Chargeishvili B, Charlton DG, Charman TP, Chau CC, Che S, Chekanov S, Chekulaev SV, Chelkov GA, Chelstowska MA, Chen B, Chen C, Chen CH, Chen H, Chen J, Chen J, Chen S, Chen SJ, Chen X, Chen YH, Cheng HC, Cheng HJ, Cheplakov A, Cheremushkina E, Cherkaoui El Moursli R, Cheu E, Cheung K, Chevalérias TJA, Chevalier L, Chiarella V, Chiarelli G, Chiodini G, Chisholm AS, Chitan A, Chiu I, Chiu YH, Chizhov MV, Choi K, Chomont AR, Chouridou S, Chow YS, Chu MC, Chu X, Chudoba J, Chuinard AJ, Chwastowski JJ, Chytka L, Cieri D, Ciesla KM, Cinca D, Cindro V, Cioară IA, Ciocio A, Cirotto F, Citron ZH, Citterio M, Ciubotaru DA, Ciungu BM, Clark A, Clark MR, Clark PJ, Clement C, Coadou Y, Cobal M, Coccaro A, Cochran J, Cohen H, Coimbra AEC, Colasurdo L, Cole B, Colijn AP, Collot J, Conde Muiño P, Connell SH, Connelly IA, Constantinescu S, Conventi F, Cooper-Sarkar AM, Cormier F, Cormier KJR, Corpe LD, Corradi M, Corrigan EE, Corriveau F, Cortes-Gonzalez A, Costa MJ, Costanza F, Costanzo D, Cowan G, Cowley JW, Crane J, Cranmer K, Crawley SJ, Creager RA, Crépé-Renaudin S, Crescioli F, Cristinziani M, Croft V, Crosetti G, Cueto A, Cuhadar Donszelmann T, Cukierman AR, Cunningham WR, Czekierda S, Czodrowski P, Da Cunha Sargedas De Sousa MJ, Da Fonseca Pinto JV, Da Via C, Dabrowski W, Dachs F, Dado T, Dahbi S, Dai T, Dallapiccola C, Dam M, D'amen G, D'Amico V, Damp J, Dandoy JR, Daneri MF, Dang NP, Dann NS, Danninger M, Dao V, Darbo G, Dartsi O, Dattagupta A, Daubney T, D'Auria S, David C, Davidek T, Davis DR, Dawson I, De K, De Asmundis R, De Beurs M, De Castro S, De Cecco S, De Groot N, de Jong P, De la Torre H, De Maria A, De Pedis D, De Salvo A, De Sanctis U, De Santis M, De Santo A, De Vasconcelos Corga K, De Vivie De Regie JB, Debenedetti C, Dedovich DV, Deiana AM, Del Peso J, Delabat Diaz Y, Delgove D, Deliot F, Delitzsch CM, Della Pietra M, Della Volpe D, Dell'Acqua A, Dell'Asta L, Delmastro M, Delporte C, Delsart PA, DeMarco DA, Demers S, Demichev M, Demontigny G, Denisov SP, D'Eramo L, Derendarz D, Derkaoui JE, Derue F, Dervan P, Desch K, Deterre C, Dette K, Deutsch C, Devesa MR, Deviveiros PO, Dewhurst A, Di Bello FA, Di Ciaccio A, Di Ciaccio L, Di Clemente WK, Di Donato C, Di Girolamo A, Di Gregorio G, Di Micco B, Di Nardo R, Di Petrillo KF, Di Sipio R, Di Valentino D, Diaconu C, Dias FA, Dias Do Vale T, Diaz MA, Dickinson J, Diehl EB, Dietrich J, Díez Cornell S, Dimitrievska A, Ding W, Dingfelder J, Dittus F, Djama F, Djobava T, Djuvsland JI, Do Vale MAB, Dobre M, Dodsworth D, Doglioni C, Dolejsi J, Dolezal Z, Donadelli M, Dong B, Donini J, D'onofrio A, D'Onofrio M, Dopke J, Doria A, Dova MT, Doyle AT, Drechsler E, Dreyer E, Dreyer T, Drobac AS, Du D, Duan Y, Dubinin F, Dubovsky M, Dubreuil A, Duchovni E, Duckeck G, Ducourthial A, Ducu OA, Duda D, Dudarev A, Dudder AC, Duffield EM, Duflot L, Dührssen M, Dülsen C, Dumancic M, Dumitriu AE, Duncan AK, Dunford M, Duperrin A, Duran Yildiz H, Düren M, Durglishvili A, Duschinger D, Dutta B, Duvnjak D, Dyckes GI, Dyndal M, Dysch S, Dziedzic BS, Ecker KM, Edgar RC, Eggleston MG, Eifert T, Eigen G, Einsweiler K, Ekelof T, El Jarrari H, El Kacimi M, El Kosseifi R, Ellajosyula V, Ellert M, Ellinghaus F, Elliot AA, Ellis N, Elmsheuser J, Elsing M, Emeliyanov D, Emerman A, Enari Y, Epland MB, Erdmann J, Ereditato A, Errenst M, Escalier M, Escobar C, Estrada Pastor O, Etzion E, Evans H, Ezhilov A, Fabbri F, Fabbri L, Fabiani V, Facini G, Faisca Rodrigues Pereira RM, Fakhrutdinov RM, Falciano S, Falke PJ, Falke S, Faltova J, Fang Y, Fang Y, Fanourakis G, Fanti M, Faraj M, Farbin A, Farilla A, Farina EM, Farooque T, Farrell S, Farrington SM, Farthouat P, Fassi F, Fassnacht P, Fassouliotis D, Faucci Giannelli M, Fawcett WJ, Fayard L, Fedin OL, Fedorko W, Fehr A, Feickert M, Feligioni L, Fell A, Feng C, Feng M, Fenton MJ, Fenyuk AB, Ferguson SW, Ferrando J, Ferrante A, Ferrari A, Ferrari P, Ferrari R, Ferreira de Lima DE, Ferrer A, Ferrere D, Ferretti C, Fiedler F, Filipčič A, Filthaut F, Finelli KD, Fiolhais MCN, Fiorini L, Fischer F, Fisher WC, Fleck I, Fleischmann P, Fletcher RRM, Flick T, Flierl BM, Flores L, Flores Castillo LR, Follega FM, Fomin N, Foo JH, Forcolin GT, Formica A, Förster FA, Forti AC, Foster AG, Foti MG, Fournier D, Fox H, Francavilla P, Francescato S, Franchini M, Franchino S, Francis D, Franconi L, Franklin M, Fray AN, Freeman PM, Freund B, Freund WS, Freundlich EM, Frizzell DC, Froidevaux D, Frost JA, Fukunaga C, Fullana Torregrosa E, Fumagalli E, Fusayasu T, Fuster J, Gabrielli A, Gabrielli A, Gadatsch S, Gadow P, Gagliardi G, Gagnon LG, Galea C, Galhardo B, Gallardo GE, Gallas EJ, Gallop BJ, Galster G, Gamboa Goni R, Gan KK, Ganguly S, Gao J, Gao Y, Gao YS, García C, García Navarro JE, García Pascual JA, Garcia-Argos C, Garcia-Sciveres M, Gardner RW, Garelli N, Gargiulo S, Garonne V, Gaspar P, Gaudiello A, Gaudio G, Gavrilenko IL, Gavrilyuk A, Gay C, Gaycken G, Gazis EN, Geanta AA, Gee CM, Gee CNP, Geisen J, Geisen M, Gemme C, Genest MH, Geng C, Gentile S, George S, Geralis T, Gerlach LO, Gessinger-Befurt P, Gessner G, Ghasemi S, Ghasemi Bostanabad M, Ghneimat M, Ghosh A, Ghosh A, Giacobbe B, Giagu S, Giangiacomi N, Giannetti P, Giannini A, Giannini G, Gibson SM, Gignac M, Gillberg D, Gilles G, Gingrich DM, Giordani MP, Giorgi FM, Giraud PF, Giugliarelli G, Giugni D, Giuli F, Gkaitatzis S, Gkialas I, Gkougkousis EL, Gkountoumis P, Gladilin LK, Glasman C, Glatzer J, Glaysher PCF, Glazov A, Gledhill GR, Goblirsch-Kolb M, Godin D, Goldfarb S, Golling T, Golubkov D, Gomes A, Goncalves Gama R, Gonçalo R, Gonella G, Gonella L, Gongadze A, Gonnella F, Gonski JL, González de la Hoz S, Gonzalez-Sevilla S, Gonzalvo Rodriguez GR, Goossens L, Gorasia NA, Gorbounov PA, Gordon HA, Gorini B, Gorini E, Gorišek A, Goshaw AT, Gostkin MI, Gottardo CA, Gouighri M, Goujdami D, Goussiou AG, Govender N, Goy C, Gozani E, Grabowska-Bold I, Graham EC, Gramling J, Gramstad E, Grancagnolo S, Grandi M, Gratchev V, Gravila PM, Gravili FG, Gray C, Gray HM, Grefe C, Gregersen K, Gregor IM, Grenier P, Grevtsov K, Grieco C, Grieser NA, Grillo AA, Grimm K, Grinstein S, Grivaz JF, Groh S, Gross E, Grosse-Knetter J, Grout ZJ, Grud C, Grummer A, Guan L, Guan W, Gubbels C, Guenther J, Guerguichon A, Guerrero Rojas JGR, Guescini F, Guest D, Gugel R, Guillemin T, Guindon S, Gul U, Guo J, Guo W, Guo Y, Guo Z, Gupta R, Gurbuz S, Gustavino G, Guth M, Gutierrez P, Gutschow C, Guyot C, Gwenlan C, Gwilliam CB, Haas A, Haber C, Hadavand HK, Haddad N, Hadef A, Hageböck S, Haleem M, Haley J, Halladjian G, Hallewell GD, Hamacher K, Hamal P, Hamano K, Hamdaoui H, Hamer M, Hamity GN, Han K, Han L, Han S, Han YF, Hanagaki K, Hance M, Handl DM, Haney B, Hankache R, Hansen E, Hansen JB, Hansen JD, Hansen MC, Hansen PH, Hanson EC, Hara K, Harenberg T, Harkusha S, Harrison PF, Hartmann NM, Hasegawa Y, Hasib A, Hassani S, Haug S, Hauser R, Havener LB, Havranek M, Hawkes CM, Hawkings RJ, Hayden D, Hayes C, Hayes RL, Hays CP, Hays JM, Hayward HS, Haywood SJ, He F, Heath MP, Hedberg V, Heelan L, Heer S, Heidegger KK, Heidorn WD, Heilman J, Heim S, Heim T, Heinemann B, Heinrich JJ, Heinrich L, Hejbal J, Helary L, Held A, Hellesund S, Helling CM, Hellman S, Helsens C, Henderson RCW, Heng Y, Henkelmann L, Henkelmann S, Henriques Correia AM, Herbert GH, Herde H, Herget V, Hernández Jiménez Y, Herr H, Herrmann MG, Herrmann T, Herten G, Hertenberger R, Hervas L, Herwig TC, Hesketh GG, Hessey NP, Higashida A, Higashino S, Higón-Rodriguez E, Hildebrand K, Hill E, Hill JC, Hill KK, Hiller KH, Hillier SJ, Hils M, Hinchliffe I, Hinterkeuser F, Hirose M, Hirose S, Hirschbuehl D, Hiti B, Hladik O, Hlaluku DR, Hoad X, Hobbs J, Hod N, Hodgkinson MC, Hoecker A, Hohn D, Hohov D, Holm T, Holmes TR, Holzbock M, Hommels LBAH, Honda S, Hong TM, Honig JC, Hönle A, Hooberman BH, Hopkins WH, Horii Y, Horn P, Horyn LA, Hou S, Hoummada A, Howarth J, Hoya J, Hrabovsky M, Hrdinka J, Hristova I, Hrivnac J, Hrynevich A, Hryn'ova T, Hsu PJ, Hsu SC, Hu Q, Hu S, Hu YF, Huang DP, Huang Y, Huang Y, Hubacek Z, Hubaut F, Huebner M, Huegging F, Huffman TB, Huhtinen M, Hunter RFH, Huo P, Hupe AM, Huseynov N, Huston J, Huth J, Hyneman R, Hyrych S, Iacobucci G, Iakovidis G, Ibragimov I, Iconomidou-Fayard L, Idrissi Z, Iengo P, Ignazzi R, Igonkina O, Iguchi R, Iizawa T, Ikegami Y, Ikeno M, Iliadis D, Ilic N, Iltzsche F, Introzzi G, Iodice M, Iordanidou K, Ippolito V, Isacson MF, Ishino M, Islam W, Issever C, Istin S, Ito F, Iturbe Ponce JM, Iuppa R, Ivina A, Iwasaki H, Izen JM, Izzo V, Jacka P, Jackson P, Jacobs RM, Jaeger BP, Jain V, Jäkel G, Jakobi KB, Jakobs K, Jakoubek T, Jamieson J, Janas KW, Jansky R, Janssen J, Janus M, Janus PA, Jarlskog G, Javadov N, Javůrek T, Javurkova M, Jeanneau F, Jeanty L, Jejelava J, Jelinskas A, Jenni P, Jeong J, Jeong N, Jézéquel S, Ji H, Jia J, Jiang H, Jiang Y, Jiang Z, Jiggins S, Jimenez Morales FA, Jimenez Pena J, Jin S, Jinaru A, Jinnouchi O, Jivan H, Johansson P, Johns KA, Johnson CA, Jon-And K, Jones RWL, Jones SD, Jones S, Jones TJ, Jongmanns J, Jorge PM, Jovicevic J, Ju X, Junggeburth JJ, Juste Rozas A, Kaczmarska A, Kado M, Kagan H, Kagan M, Kahn A, Kahra C, Kaji T, Kajomovitz E, Kalderon CW, Kaluza A, Kamenshchikov A, Kaneda M, Kang NJ, Kanjir L, Kano Y, Kantserov VA, Kanzaki J, Kaplan LS, Kar D, Karava K, Kareem MJ, Karpov SN, Karpova ZM, Kartvelishvili V, Karyukhin AN, Kashif L, Kass RD, Kastanas A, Kato C, Katzy J, Kawade K, Kawagoe K, Kawaguchi T, Kawamoto T, Kawamura G, Kay EF, Kazanin VF, Keeler R, Kehoe R, Keller JS, Kellermann E, Kelsey D, Kempster JJ, Kendrick J, Kennedy KE, Kepka O, Kersten S, Kerševan BP, Ketabchi Haghighat S, Khader M, Khalil-Zada F, Khandoga M, Khanov A, Kharlamov AG, Kharlamova T, Khoda EE, Khodinov A, Khoo TJ, Khramov E, Khubua J, Kido S, Kiehn M, Kilby CR, Kim YK, Kimura N, Kind OM, King BT, Kirchmeier D, Kirk J, Kiryunin AE, Kishimoto T, Kisliuk DP, Kitali V, Kivernyk O, Klapdor-Kleingrothaus T, Klassen M, Klein MH, Klein M, Klein U, Kleinknecht K, Klimek P, Klimentov A, Klingl T, Klioutchnikova T, Klitzner FF, Kluit P, Kluth S, Kneringer E, Knoops EBFG, Knue A, Kobayashi D, Kobayashi T, Kobel M, Kocian M, Kodys P, Koenig PT, Koffas T, Köhler NM, Koi T, Kolb M, Koletsou I, Komarek T, Kondo T, Köneke K, Kong AXY, König AC, Kono T, Konoplich R, Konstantinides V, Konstantinidis N, Konya B, Kopeliansky R, Koperny S, Korcyl K, Kordas K, Koren G, Korn A, Korolkov I, Korolkova EV, Korotkova N, Kortner O, Kortner S, Kosek T, Kostyukhin VV, Kotsokechagia A, Kotwal A, Koulouris A, Kourkoumeli-Charalampidi A, Kourkoumelis C, Kourlitis E, Kouskoura V, Kowalewska AB, Kowalewski R, Kozakai C, Kozanecki W, Kozhin AS, Kramarenko VA, Kramberger G, Krasnopevtsev D, Krasny MW, Krasznahorkay A, Krauss D, Kremer JA, Kretzschmar J, Krieger P, Krieter F, Krishnan A, Krizka K, Kroeninger K, Kroha H, Kroll J, Kroll J, Krowpman KS, Krstic J, Kruchonak U, Krüger H, Krumnack N, Kruse MC, Krzysiak JA, Kubota T, Kuchinskaia O, Kuday S, Kuechler JT, Kuehn S, Kugel A, Kuhl T, Kukhtin V, Kukla R, Kulchitsky Y, Kuleshov S, Kulinich YP, Kuna M, Kunigo T, Kupco A, Kupfer T, Kuprash O, Kurashige H, Kurchaninov LL, Kurochkin YA, Kurova A, Kurth MG, Kuwertz ES, Kuze M, Kvam AK, Kvita J, Kwan T, La Rosa A, La Rotonda L, La Ruffa F, Lacasta C, Lacava F, Lack DPJ, Lacker H, Lacour D, Ladygin E, Lafaye R, Laforge B, Lagouri T, Lai S, Lakomiec IK, Lammers S, Lampl W, Lampoudis C, Lançon E, Landgraf U, Landon MPJ, Lanfermann MC, Lang VS, Lange JC, Langenberg RJ, Lankford AJ, Lanni F, Lantzsch K, Lanza A, Lapertosa A, Laplace S, Laporte JF, Lari T, Lasagni Manghi F, Lassnig M, Lau TS, Laudrain A, Laurier A, Lavorgna M, Lawlor SD, Lazzaroni M, Le B, Le Guirriec E, LeBlanc M, LeCompte T, Ledroit-Guillon F, Lee ACA, Lee CA, Lee GR, Lee L, Lee SC, Lee SJ, Lee S, Lefebvre B, Lefebvre HP, Lefebvre M, Legger F, Leggett C, Lehmann K, Lehmann N, Lehmann Miotto G, Leight WA, Leisos A, Leite MAL, Leitgeb CE, Leitner R, Lellouch D, Leney KJC, Lenz T, Leone R, Leone S, Leonidopoulos C, Leopold A, Leroy C, Les R, Lester CG, Levchenko M, Levêque J, Levin D, Levinson LJ, Lewis DJ, Li B, Li B, Li CQ, Li F, Li H, Li H, Li J, Li K, Li L, Li M, Li Q, Li QY, Li S, Li X, Li Y, Li Z, Liang Z, Liberti B, Liblong A, Lie K, Lim S, Lin CY, Lin K, Lin TH, Linck RA, Lindon JH, Lionti AL, Lipeles E, Lipniacka A, Liss TM, Lister A, Litke AM, Little JD, Liu B, Liu BL, Liu HB, Liu H, Liu JB, Liu JKK, Liu K, Liu M, Liu P, Liu Y, Liu YL, Liu YW, Livan M, Lleres A, Llorente Merino J, Lloyd SL, Lo CY, Lo Sterzo F, Lobodzinska EM, Loch P, Loffredo S, Lohse T, Lohwasser K, Lokajicek M, Long JD, Long RE, Longo L, Looper KA, Lopez JA, Lopez Paz I, Lopez Solis A, Lorenz J, Lorenzo Martinez N, Lory AM, Losada M, Lösel PJ, Lösle A, Lou X, Lou X, Lounis A, Love J, Love PA, Lozano Bahilo JJ, Lu M, Lu YJ, Lubatti HJ, Luci C, Lucotte A, Luedtke C, Luehring F, Luise I, Luminari L, Lund-Jensen B, Lutz MS, Lynn D, Lyons H, Lysak R, Lytken E, Lyu F, Lyubushkin V, Lyubushkina T, Ma H, Ma LL, Ma Y, Maccarrone G, Macchiolo A, Macdonald CM, Machado Miguens J, Madaffari D, Madar R, Mader WF, Madysa N, Maeda J, Maeno T, Maerker M, Maevskiy AS, Magerl V, Magini N, Mahon DJ, Maidantchik C, Maier T, Maio A, Maj K, Majersky O, Majewski S, Makida Y, Makovec N, Malaescu B, Malecki P, Maleev VP, Malek F, Mallik U, Malon D, Malone C, Maltezos S, Malyukov S, Mamuzic J, Mancini G, Mandić I, Manhaes de Andrade Filho L, Maniatis IM, Manjarres Ramos J, Mankinen KH, Mann A, Manousos A, Mansoulie B, Manthos I, Manzoni S, Marantis A, Marceca G, Marchese L, Marchiori G, Marcisovsky M, Marcoccia L, Marcon C, Marin Tobon CA, Marjanovic M, Marshall Z, Martensson MUF, Marti-Garcia S, Martin CB, Martin TA, Martin VJ, Martin Dit Latour B, Martinelli L, Martinez M, Martinez Outschoorn VI, Martin-Haugh S, Martoiu VS, Martyniuk AC, Marzin A, Maschek SR, Masetti L, Mashimo T, Mashinistov R, Masik J, Maslennikov AL, Massa L, Massarotti P, Mastrandrea P, Mastroberardino A, Masubuchi T, Matakias D, Matic A, Matsuzawa N, Mättig P, Maurer J, Maček B, Maximov DA, Mazini R, Maznas I, Mazza SM, Mc Kee SP, McCarthy TG, McCormack WP, McDonald EF, Mcfayden JA, Mchedlidze G, McKay MA, McLean KD, McMahon SJ, McNamara PC, McNicol CJ, McPherson RA, Mdhluli JE, Meadows ZA, Meehan S, Megy T, Mehlhase S, Mehta A, Meideck T, Meirose B, Melini D, Mellado Garcia BR, Mellenthin JD, Melo M, Meloni F, Melzer A, Menary SB, Mendes Gouveia ED, Meng L, Meng XT, Menke S, Meoni E, Mergelmeyer S, Merkt SAM, Merlassino C, Mermod P, Merola L, Meroni C, Merz G, Meshkov O, Meshreki JKR, Messina A, Metcalfe J, Mete AS, Meyer C, Meyer JP, Meyer Zu Theenhausen H, Miano F, Michetti M, Middleton RP, Mijović L, Mikenberg G, Mikestikova M, Mikuž M, Mildner H, Milesi M, Milic A, Millar DA, Miller DW, Milov A, Milstead DA, Mina RA, Minaenko AA, Miñano Moya M, Minashvili IA, Mincer AI, Mindur B, Mineev M, Minegishi Y, Mir LM, Mirto A, Mistry KP, Mitani T, Mitrevski J, Mitsou VA, Mittal M, Miu O, Miucci A, Miyagawa PS, Mizukami A, Mjörnmark JU, Mkrtchyan T, Mlynarikova M, Moa T, Mochizuki K, Mogg P, Mohapatra S, Moles-Valls R, Mondragon MC, Mönig K, Monk J, Monnier E, Montalbano A, Montejo Berlingen J, Montella M, Monticelli F, Monzani S, Morange N, Moreno D, Moreno Llácer M, Moreno Martinez C, Morettini P, Morgenstern M, Morgenstern S, Mori D, Morii M, Morinaga M, Morisbak V, Morley AK, Mornacchi G, Morris AP, Morvaj L, Moschovakos P, Moser B, Mosidze M, Moskalets T, Moss HJ, Moss J, Moyse EJW, Muanza S, Mueller J, Mueller RSP, Muenstermann D, Mullier GA, Mungo DP, Munoz Martinez JL, Munoz Sanchez FJ, Murin P, Murray WJ, Murrone A, Muškinja M, Mwewa C, Myagkov AG, Myers AA, Myers J, Myska M, Nachman BP, Nackenhorst O, Nag AN, Nagai K, Nagano K, Nagasaka Y, Nagle JL, Nagy E, Nairz AM, Nakahama Y, Nakamura K, Nakamura T, Nakano I, Nanjo H, Napolitano F, Naranjo Garcia RF, Narayan R, Naryshkin I, Naumann T, Navarro G, Nechaeva PY, Nechansky F, Neep TJ, Negri A, Negrini M, Nellist C, Nelson ME, Nemecek S, Nemethy P, Nessi M, Neubauer MS, Neumann M, Newhouse R, Newman PR, Ng YS, Ng YWY, Ngair B, Nguyen HDN, Nguyen Manh T, Nibigira E, Nickerson RB, Nicolaidou R, Nielsen DS, Nielsen J, Nikiforou N, Nikolaenko V, Nikolic-Audit I, Nikolopoulos K, Nilsson P, Nindhito HR, Ninomiya Y, Nisati A, Nishu N, Nisius R, Nitsche I, Nitta T, Nobe T, Noguchi Y, Nomidis I, Nomura MA, Nordberg M, Norjoharuddeen N, Novak T, Novgorodova O, Novotny R, Nozka L, Ntekas K, Nurse E, Oakham FG, Oberlack H, Ocariz J, Ochi A, Ochoa I, Ochoa-Ricoux JP, O'Connor K, Oda S, Odaka S, Oerdek S, Ogrodnik A, Oh A, Oh SH, Ohm CC, Oide H, Ojeda ML, Okawa H, Okazaki Y, O'Keefe MW, Okumura Y, Okuyama T, Olariu A, Oleiro Seabra LF, Olivares Pino SA, Oliveira Damazio D, Oliver JL, Olsson MJR, Olszewski A, Olszowska J, O'Neil DC, O'neill AP, Onofre A, Onyisi PUE, Oppen H, Oreglia MJ, Orellana GE, Orestano D, Orlando N, Orr RS, O'Shea V, Ospanov R, Otero Y Garzon G, Otono H, Ott PS, Ouchrif M, Ouellette J, Ould-Saada F, Ouraou A, Ouyang Q, Owen M, Owen RE, Ozcan VE, Ozturk N, Pacalt J, Pacey HA, Pachal K, Pacheco Pages A, Padilla Aranda C, Pagan Griso S, Paganini M, Palacino G, Palazzo S, Palestini S, Palka M, Pallin D, Panagoulias I, Pandini CE, Panduro Vazquez JG, Pani P, Panizzo G, Paolozzi L, Papadatos C, Papageorgiou K, Parajuli S, Paramonov A, Paredes Hernandez D, Paredes Saenz SR, Parida B, Park TH, Parker AJ, Parker MA, Parodi F, Parrish EW, Parsons JA, Parzefall U, Pascual Dominguez L, Pascuzzi VR, Pasner JMP, Pasquali F, Pasqualucci E, Passaggio S, Pastore F, Pasuwan P, Pataraia S, Pater JR, Pathak A, Pauly T, Pearkes J, Pearson B, Pedersen M, Pedraza Diaz L, Pedro R, Peiffer T, Peleganchuk SV, Penc O, Peng H, Peralva BS, Perego MM, Pereira Peixoto AP, Perepelitsa DV, Peri F, Perini L, Pernegger H, Perrella S, Perrevoort A, Peters K, Peters RFY, Petersen BA, Petersen TC, Petit E, Petridis A, Petridou C, Petroff P, Petrov M, Petrucci F, Pettee M, Pettersson NE, Petukhova K, Peyaud A, Pezoa R, Pezzotti L, Pham T, Phillips FH, Phillips PW, Phipps MW, Piacquadio G, Pianori E, Picazio A, Pickles RH, Piegaia R, Pietreanu D, Pilcher JE, Pilkington AD, Pinamonti M, Pinfold JL, Pitt M, Pizzimento L, Pleier MA, Pleskot V, Plotnikova E, Podberezko P, Poettgen R, Poggi R, Poggioli L, Pogrebnyak I, Pohl D, Pokharel I, Polesello G, Poley A, Policicchio A, Polifka R, Polini A, Pollard CS, Polychronakos V, Ponomarenko D, Pontecorvo L, Popa S, Popeneciu GA, Portales L, Portillo Quintero DM, Pospisil S, Potamianos K, Potrap IN, Potter CJ, Potti H, Poulsen T, Poveda J, Powell TD, Pownall G, Pozo Astigarraga ME, Pralavorio P, Prell S, Price D, Primavera M, Prince S, Proffitt ML, Proklova N, Prokofiev K, Prokoshin F, Protopopescu S, Proudfoot J, Przybycien M, Pudzha D, Puri A, Puzo P, Qian J, Qin Y, Quadt A, Queitsch-Maitland M, Qureshi A, Racko M, Ragusa F, Rahal G, Raine JA, Rajagopalan S, Ramirez Morales A, Ran K, Rashid T, Raspopov S, Rauch DM, Rauscher F, Rave S, Ravina B, Ravinovich I, Rawling JH, Raymond M, Read AL, Readioff NP, Reale M, Rebuzzi DM, Redelbach A, Redlinger G, Reeves K, Rehnisch L, Reichert J, Reikher D, Reiss A, Rej A, Rembser C, Renda M, Rescigno M, Resconi S, Resseguie ED, Rettie S, Reynolds B, Reynolds E, Rezanova OL, Reznicek P, Ricci E, Richter R, Richter S, Richter-Was E, Ricken O, Ridel M, Rieck P, Rifki O, Rijssenbeek M, Rimoldi A, Rimoldi M, Rinaldi L, Ripellino G, Riu I, Rivera Vergara JC, Rizatdinova F, Rizvi E, Rizzi C, Roberts RT, Robertson SH, Robin M, Robinson D, Robinson JEM, Robles Gajardo CM, Robson A, Rocchi A, Rocco E, Roda C, Rodriguez Bosca S, Rodriguez Perez A, Rodriguez Rodriguez D, Rodríguez Vera AM, Roe S, Røhne O, Röhrig R, Rojas RA, Roland CPA, Roloff J, Romaniouk A, Romano M, Rompotis N, Ronzani M, Roos L, Rosati S, Rosin G, Rosser BJ, Rossi E, Rossi E, Rossi E, Rossi LP, Rossini L, Rosten R, Rotaru M, Rothberg J, Rousseau D, Rovelli G, Roy A, Roy D, Rozanov A, Rozen Y, Ruan X, Rühr F, Ruiz-Martinez A, Rummler A, Rurikova Z, Rusakovich NA, Russell HL, Rustige L, Rutherfoord JP, Rüttinger EM, Rybar M, Rybkin G, Rye EB, Ryzhov A, Sabater Iglesias JA, Sabatini P, Sabato G, Sacerdoti S, Sadrozinski HFW, Sadykov R, Safai Tehrani F, Safarzadeh Samani B, Saha P, Saha S, Sahinsoy M, Sahu A, Saimpert M, Saito M, Saito T, Sakamoto H, Sakharov A, Salamani D, Salamanna G, Salazar Loyola JE, Salnikov A, Salt J, Salvatore D, Salvatore F, Salvucci A, Salzburger A, Samarati J, Sammel D, Sampsonidis D, Sampsonidou D, Sánchez J, Sanchez Pineda A, Sandaker H, Sander CO, Sanderswood IG, Sandhoff M, Sandoval C, Sankey DPC, Sannino M, Sano Y, Sansoni A, Santoni C, Santos H, Santpur SN, Santra A, Sapronov A, Saraiva JG, Sasaki O, Sato K, Sauerburger F, Sauvan E, Savard P, Savic N, Sawada R, Sawyer C, Sawyer L, Sbarra C, Sbrizzi A, Scanlon T, Schaarschmidt J, Schacht P, Schachtner BM, Schaefer D, Schaefer L, Schaeffer J, Schaepe S, Schäfer U, Schaffer AC, Schaile D, Schamberger RD, Scharmberg N, Schegelsky VA, Scheirich D, Schenck F, Schernau M, Schiavi C, Schier S, Schildgen LK, Schillaci ZM, Schioppa EJ, Schioppa M, Schleicher KE, Schlenker S, Schmidt-Sommerfeld KR, Schmieden K, Schmitt C, Schmitt S, Schmitz S, Schmoeckel JC, Schnoor U, Schoeffel L, Schoening A, Scholer PG, Schopf E, Schott M, Schouwenberg JFP, Schovancova J, Schramm S, Schroeder F, Schulte A, Schultz-Coulon HC, Schumacher M, Schumm BA, Schune P, Schwartzman A, Schwarz TA, Schwemling P, Schwienhorst R, Sciandra A, Sciolla G, Scodeggio M, Scornajenghi M, Scuri F, Scutti F, Scyboz LM, Sebastiani CD, Seema P, Seidel SC, Seiden A, Seidlitz BD, Seiss T, Seixas JM, Sekhniaidze G, Sekhon K, Sekula SJ, Semprini-Cesari N, Sen S, Serfon C, Serin L, Serkin L, Sessa M, Severini H, Šfiligoj T, Sforza F, Sfyrla A, Shabalina E, Shahinian JD, Shaikh NW, Shaked Renous D, Shan LY, Shank JT, Shapiro M, Sharma A, Sharma AS, Shatalov PB, Shaw K, Shaw SM, Shehade M, Shen Y, Sherman AD, Sherwood P, Shi L, Shimizu S, Shimmin CO, Shimogama Y, Shimojima M, Shipsey IPJ, Shirabe S, Shiyakova M, Shlomi J, Shmeleva A, Shochet MJ, Shojaii J, Shope DR, Shrestha S, Shrif EM, Shulga E, Sicho P, Sickles AM, Sidebo PE, Sideras Haddad E, Sidiropoulou O, Sidoti A, Siegert F, Sijacki D, Silva M, Silva Oliveira MV, Silverstein SB, Simion S, Simoniello R, Simsek S, Sinervo P, Sinetckii V, Sinev NB, Singh S, Sioli M, Siral I, Sivoklokov SY, Sjölin J, Skorda E, Skubic P, Slawinska M, Sliwa K, Slovak R, Smakhtin V, Smart BH, Smiesko J, Smirnov N, Smirnov SY, Smirnov Y, Smirnova LN, Smirnova O, Smith JW, Smizanska M, Smolek K, Smykiewicz A, Snesarev AA, Snoek HL, Snyder IM, Snyder S, Sobie R, Soffer A, Søgaard A, Sohns F, Solans Sanchez CA, Soldatov EY, Soldevila U, Solodkov AA, Soloshenko A, Solovyanov OV, Solovyev V, Sommer P, Son H, Song W, Song WY, Sopczak A, Sopio AL, Sopkova F, Sotiropoulou CL, Sottocornola S, Soualah R, Soukharev AM, South D, Spagnolo S, Spalla M, Spangenberg M, Spanò F, Sperlich D, Spieker TM, Spighi R, Spigo G, Spina M, Spiteri DP, Spousta M, Stabile A, Stamas BL, Stamen R, Stamenkovic M, Stanecka E, Stanislaus B, Stanitzki MM, Stankaityte M, Stapf B, Starchenko EA, Stark GH, Stark J, Stark SH, Staroba P, Starovoitov P, Stärz S, Staszewski R, Stavropoulos G, Stegler M, Steinberg P, Steinhebel AL, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stevenson TJ, Stewart GA, Stockton MC, Stoicea G, Stolarski M, Stonjek S, Straessner A, Strandberg J, Strandberg S, Strauss M, Strizenec P, Ströhmer R, Strom DM, Stroynowski R, Strubig A, Stucci SA, Stugu B, Stupak J, Styles NA, Su D, Suchek S, Sulin VV, Sullivan MJ, Sultan DMS, Sultansoy S, Sumida T, Sun S, Sun X, Suruliz K, Suster CJE, Sutton MR, Suzuki S, Svatos M, Swiatlowski M, Swift SP, Swirski T, Sydorenko A, Sykora I, Sykora M, Sykora T, Ta D, Tackmann K, Taenzer J, Taffard A, Tafirout R, Takai H, Takashima R, Takeda K, Takeshita T, Takeva EP, Takubo Y, Talby M, Talyshev AA, Tamir NM, Tanaka J, Tanaka M, Tanaka R, Tapia Araya S, Tapprogge S, Tarek Abouelfadl Mohamed A, Tarem S, Tariq K, Tarna G, Tartarelli GF, Tas P, Tasevsky M, Tashiro T, Tassi E, Tavares Delgado A, Tayalati Y, Taylor AJ, Taylor GN, Taylor W, Tee AS, Teixeira De Lima R, Teixeira-Dias P, Ten Kate H, Teoh JJ, Terada S, Terashi K, Terron J, Terzo S, Testa M, Teuscher RJ, Thais SJ, Theveneaux-Pelzer T, Thiele F, Thomas DW, Thomas JO, Thomas JP, Thompson AS, Thompson PD, Thomsen LA, Thomson E, Thorpe EJ, Ticse Torres RE, Tikhomirov VO, Tikhonov YA, Timoshenko S, Tipton P, Tisserant S, Todome K, Todorova-Nova S, Todt S, Tojo J, Tokár S, Tokushuku K, Tolley E, Tomiwa KG, Tomoto M, Tompkins L, Tong B, Tornambe P, Torrence E, Torres H, Torró Pastor E, Tosciri C, Toth J, Tovey DR, Traeet A, Treado CJ, Trefzger T, Tresoldi F, Tricoli A, Trigger IM, Trincaz-Duvoid S, Trischuk DA, Trischuk W, Trocmé B, Trofymov A, Troncon C, Trovatelli M, Trovato F, Truong L, Trzebinski M, Trzupek A, Tsai F, Tseng JCL, Tsiareshka PV, Tsirigotis A, Tsiskaridze V, Tskhadadze EG, Tsopoulou M, Tsukerman II, Tsulaia V, Tsuno S, Tsybychev D, Tu Y, Tudorache A, Tudorache V, Tulbure TT, Tuna AN, Turchikhin S, Turgeman D, Turk Cakir I, Turner RJ, Turra RT, Tuts PM, Tzamarias S, Tzovara E, Ucchielli G, Uchida K, Ueda I, Ukegawa F, Unal G, Undrus A, Unel G, Ungaro FC, Unno Y, Uno K, Urban J, Urquijo P, Usai G, Uysal Z, Vacek V, Vachon B, Vadla KOH, Vaidya A, Valderanis C, Valdes Santurio E, Valente M, Valentinetti S, Valero A, Valéry L, Vallance RA, Vallier A, Valls Ferrer JA, Van Daalen TR, Van Gemmeren P, Van Vulpen I, Vanadia M, Vandelli W, Vandenbroucke M, Vandewall ER, Vaniachine A, Vannicola D, Vari R, Varnes EW, Varni C, Varol T, Varouchas D, Varvell KE, Vasile ME, Vasquez GA, Vazeille F, Vazquez Furelos D, Vazquez Schroeder T, Veatch J, Vecchio V, Veen MJ, Veloce LM, Veloso F, Veneziano S, Ventura A, Venturi N, Verbytskyi A, Vercesi V, Verducci M, Vergel Infante CM, Vergis C, Verkerke W, Vermeulen AT, Vermeulen JC, Vetterli MC, Viaux Maira N, Vicente Barreto Pinto M, Vickey T, Vickey Boeriu OE, Viehhauser GHA, Vigani L, Villa M, Villaplana Perez M, Vilucchi E, Vincter MG, Virdee GS, Vishwakarma A, Vittori C, Vivarelli I, Vogel M, Vokac P, von Buddenbrock SE, Von Toerne E, Vorobel V, Vorobev K, Vos M, Vossebeld JH, Vozak M, Vranjes N, Vranjes Milosavljevic M, Vrba V, Vreeswijk M, Vuillermet R, Vukotic I, Wagner P, Wagner W, Wagner-Kuhr J, Wahdan S, Wahlberg H, Walbrecht VM, Walder J, Walker R, Walker SD, Walkowiak W, Wallangen V, Wang AM, Wang C, Wang C, Wang F, Wang H, Wang H, Wang J, Wang J, Wang J, Wang P, Wang Q, Wang RJ, Wang R, Wang R, Wang SM, Wang WT, Wang W, Wang WX, Wang Y, Wang Z, Wanotayaroj C, Warburton A, Ward CP, Wardrope DR, Warrack N, Washbrook A, Watson AT, Watson MF, Watts G, Waugh BM, Webb AF, Webb S, Weber C, Weber MS, Weber SA, Weber SM, Weidberg AR, Weingarten J, Weirich M, Weiser C, Wells PS, Wenaus T, Wengler T, Wenig S, Wermes N, Werner MD, Wessels M, Weston TD, Whalen K, Whallon NL, Wharton AM, White AS, White A, White MJ, Whiteson D, Whitmore BW, Wiedenmann W, Wielers M, Wieseotte N, Wiglesworth C, Wiik-Fuchs LAM, Wilk F, Wilkens HG, Wilkins LJ, Williams HH, Williams S, Willis C, Willocq S, Wilson JA, Wingerter-Seez I, Winkels E, Winklmeier F, Winston OJ, Winter BT, Wittgen M, Wobisch M, Wolf A, Wolf TMH, Wolff R, Wölker R, Wollrath J, Wolter MW, Wolters H, Wong VWS, Woods NL, Worm SD, Wosiek BK, Woźniak KW, Wraight K, Wu SL, Wu X, Wu Y, Wyatt TR, Wynne BM, Xella S, Xi Z, Xia L, Xiao X, Xiotidis I, Xu D, Xu H, Xu L, Xu T, Xu W, Xu Z, Xu Z, Yabsley B, Yacoob S, Yajima K, Yallup DP, Yamaguchi N, Yamaguchi Y, Yamamoto A, Yamatani M, Yamazaki T, Yamazaki Y, Yan Z, Yang HJ, Yang HT, Yang S, Yang X, Yang Y, Yao WM, Yap YC, Yasu Y, Yatsenko E, Ye J, Ye S, Yeletskikh I, Yexley MR, Yigitbasi E, Yorita K, Yoshihara K, Young CJS, Young C, Yu J, Yuan R, Yue X, Yuen SPY, Zaazoua M, Zabinski B, Zacharis G, Zaffaroni E, Zahreddine J, Zaitsev AM, Zakareishvili T, Zakharchuk N, Zambito S, Zanzi D, Zaripovas DR, Zeißner SV, Zeitnitz C, Zemaityte G, Zeng JC, Zenin O, Ženiš T, Zerwas D, Zgubič M, Zhang B, Zhang DF, Zhang G, Zhang H, Zhang J, Zhang L, Zhang L, Zhang M, Zhang R, Zhang S, Zhang X, Zhang Y, Zhang Z, Zhang Z, Zhao P, Zhao Y, Zhao Z, Zhemchugov A, Zheng Z, Zhong D, Zhou B, Zhou C, Zhou MS, Zhou M, Zhou N, Zhou Y, Zhu CG, Zhu C, Zhu HL, Zhu H, Zhu J, Zhu Y, Zhuang X, Zhukov K, Zhulanov V, Zieminska D, Zimine NI, Zimmermann S, Zinonos Z, Ziolkowski M, Živković L, Zobernig G, Zoccoli A, Zoch K, Zorbas TG, Zou R, Zwalinski L. Measurement of the Lund Jet Plane Using Charged Particles in 13 TeV Proton-Proton Collisions with the ATLAS Detector. PHYSICAL REVIEW LETTERS 2020; 124:222002. [PMID: 32567910 DOI: 10.1103/physrevlett.124.222002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Revised: 05/06/2020] [Accepted: 05/13/2020] [Indexed: 06/11/2023]
Abstract
The prevalence of hadronic jets at the LHC requires that a deep understanding of jet formation and structure is achieved in order to reach the highest levels of experimental and theoretical precision. There have been many measurements of jet substructure at the LHC and previous colliders, but the targeted observables mix physical effects from various origins. Based on a recent proposal to factorize physical effects, this Letter presents a double-differential cross-section measurement of the Lund jet plane using 139 fb^{-1} of sqrt[s]=13 TeV proton-proton collision data collected with the ATLAS detector using jets with transverse momentum above 675 GeV. The measurement uses charged particles to achieve a fine angular resolution and is corrected for acceptance and detector effects. Several parton shower Monte Carlo models are compared with the data. No single model is found to be in agreement with the measured data across the entire plane.
Collapse
|
47
|
Tabuchi Y, Hashimoto M, Akizuki S, Nakashima R, Murakami K, Yoshifuji H, Tanaka M, Ohmura K. SAT0349 CTLA4-IG DECREASES TH17 CELL LEVELS BUT MAINTAINS ILC3S WITH AN INCREASE IN THE ILC3/ILC1 RATIO IN THE GUT OF SKG MICE AS A MODEL OF SPONDYLOARTHRITIS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:SKG mice have been known for their autoreactive Th17 cells resulting from the insufficient thymic negative selection due to a Zap70 mutation1,2). Under specific pathogen-free conditions, they acquire features of spondyloarthritis (SpA) by intraperitoneal injection of curdlan, a (1,3)-β-glucan3). Several reports have shown that Th17 cells also increase in human SpA4). However, CTLA4-Ig, which ameliorates rheumatoid arthritis by suppressing pathogenic cells such as effector T cells, was unable to show adequate efficacy as much as expected in SpA patients5). Around the same time, innate lymphocytes began to be focused on, in the pathogenesis of SpA, including innate lymphoid cells (ILCs), which abundantly reside in the gut6).Objectives:This study aimed to clarify the effects of CTLA4-Ig on the pathogenesis of SpA by using curdlan-treated SKG mice, focusing on type 3 immunity such as Th17 cells and ILC3s.Methods:Two- to three-month-old female SKG mice were injected intraperitoneally with 3mg of curdlan or PBS at the beginning and with 500 µg of CTLA4-Ig or PBS every other week (n=5 per group). The body weight and arthritis score were measured weekly for a month. Then, the changes in the proportion of T cells and ILCs in the spleen and Peyer’s patches (PPs) were analysed by flow cytometry (FCM). BALB/c mice, without treatment, were also examined by FCM as a control cohort. In addition, a next-generation analysis of their feces was performed on 16S ribosomal coding genes before curdlan and CTLA4-Ig treatment.Results:SKG mice contained not only more Th17 cells but also more ILC1s and ILC3s than BALB/c mice, in their guts (the PPs). The feces of SKG mice intrinsically showed a decrease in the number of bacterial species, suggesting a dysbiosis. Then, in curdlan-treated SKG mice, CTLA4-Ig administration decreased the proportion of both Th17 cells and ILC3s in the spleen, but did not decrease the proportion of ILC3s in the PPs. Moreover, the ILC3/ILC1 ratio in the PPs was from low to high in the order of SKG mice without treatment, SKG mice injected with curdlan, and SKG mice injected with both curdlan and CTLA4-Ig. The phenotype corresponding to SpA features, in curdlan-treated SKG mice, continued after repeated CTLA4-Ig administration.Conclusion:Curdlan provoked SpA features in SKG mice with an intrinsic dysbiosis. Additional CTLA4-Ig injection decreased the proportion of Th17 cells but maintained that of ILC3s with increased ILC3/ILC1 ratio in the gut. This result supports the hypothesis that in the SpA pathophysiology, a weakened acquired immunity in the gut might lead to ILC3 activation, via dysbiosis, and its continuous disease progression, suggesting that ILC3s are a promising therapeutic target in SpA.References:[1]Sakaguchi N, Sakaguchi S, et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice.Nature2003;426:454-460.[2]Hirota K, Sakaguchi S, et al. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis.J Exp Med2007;204:41-47.[3]Ruutu M, Thomas R, et al. β-glucan triggers spondylarthritis and Crohn’s disease–like ileitis in SKG mice.Arthritis Rheum2012;64:2211-2222.[4]Shen H, Gaston JS, et al. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis.Arthritis Rheum2009;60:1647-1656.[5]Song I-H, Sieper J, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study.Ann Rheum Dis2011;70:1108-1110.[6]Ciccia F, Triolo G, et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis.Ann Rheum Dis2015;74:1739-1747.Disclosure of Interests:Yuya TABUCHI Paid instructor for: Astellas Pharma, GlaxoSmithKline, Mitsubishi Tanabe Pharma, and Nippon Shinyaku., Speakers bureau: AbbVie, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Nippon Shinyaku, and Novartis Pharma., Motomu Hashimoto Grant/research support from: Bristol-Myers Squibb, Eisai, and Eli Lilly and Company., Speakers bureau: Bristol-Myers Squibb and Mitsubishi Tanabe Pharma., Syuji Akizuki: None declared, Ran Nakashima Grant/research support from: Takeda Pharmaceutical. (Outside the field of the present study.), Speakers bureau: Astellas Pharma, Medical & Biological Laboratories, AstraZeneca, and Boehringer Ingelheim. (Outside the field of the present study.), Kosaku Murakami Speakers bureau: AbbVie, Eisai, and Mitsubishi Tanabe Pharma., Hajime Yoshifuji Grant/research support from: Astellas Pharma. (Outside the field of the present study.), Speakers bureau: Chugai Pharmaceutical. (Outside the field of the present study.), Masao Tanaka Grant/research support from: AbbVie, Asahi Kasei Pharma, Astellas Pharma, Ayumi Pharmaceutical, Chugai Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Taisho Pharmaceutical, and UCB Japan., Speakers bureau: AbbVie, Asahi Kasei Pharma, Astellas Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Eli Lilly and Company, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Novartis Pharma, Pfizer, Taisho Pharmaceutical, Takeda Pharmaceutical, and UCB Japan., Koichiro Ohmura Grant/research support from: Astellas Pharma, AYUMI Pharmaceutical, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Japan Blood Products Organization, Mitsubishi Tanabe Pharma, Nippon Kayaku, Nippon Shinyaku, Sanofi, and Takeda Pharmaceutical., Speakers bureau: AbbVie, Actelion Pharmaceuticals Japan, Asahi Kasei Pharma, AYUMI Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Novartis Pharma, and Sanofi.
Collapse
|
48
|
Takase Y, Doi H, Iwasaki T, Hashimoto M, Inaba R, Kozuki T, Taniguchi M, Tabuchi Y, Kitagori K, Akizuki S, Murakami K, Nakashima R, Yoshifuji H, Yamamoto W, Tanaka M, Ohmura K. THU0285 ANALYSIS OF THE RELATIONSHIP BETWEEN ORGAN DAMAGE AND QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Systemic lupus erythematosus (SLE) is an autoimmune disease that can not only cause systemic symptoms, such as fever and arthritis, but can also damage important organs, such as those of the central nervous system and the kidneys. Prevention of irreversible organ damage is important for better prognosis [1]. Additionally, the importance of maintaining the quality of life (QOL) of patients has recently been emphasized. However, only a few studies have examined the relationship between irreversible organ damage and patient QOL.Objectives:To assess the relationship between organ damage and QOL, and to survey which organs have more significant effects on QOL.Methods:We conducted a questionnaire-based survey of 183 patients with SLE at Kyoto University Hospital from September to December 2019. We used the SLICC/ACR Damage Index (SDI) to evaluate organ damage [2]. The following five scales were employed to evaluate QOL: the physical (PCS) and mental component summary (MCS) of the Medical Outcome Study (MOS) 36-Item Short-Form Health Survey version 2.0 (SF-36v2) [3], health (HRQOL) and non-health-related QOL (N-HRQOL) of LupusPRO [4], and SLE Symptom Checklist (SSC) [5].Results:Linear regression analysis showed significant correlation between the SDI score and all QOL scales except for N-HRQOL, suggesting negative effects of organ damage on QOL (Table 1). Next, we analysed whether there was a significant difference in the SF-36 score between those who were positive and negative for each SDI item (41 in total), using the Wilcoxon rank sum test. Muscle atrophy or weakness (p= 3.0×10-10), osteoporosis with fracture or vertebral collapse (p= 9.7×10-8), claudication (p= 7.4×10-5), and cognitive impairment or major psychosis (p= 9.9×10-5) significantly correlated (p< 1.2×10-3) with PCS, and scarring chronic alopecia (p= 3.4×10-4) with MCS (Table 2). In addition, the five SDI items significantly correlated with the remaining three QOL scales (HRQOL, N-HRQOL, and SSC;p< 0.05).Table 1.Relationship between the SDI score and QOLSF-36LupusPROSSCPCSMCSHRQOLN-HRQOLp-value<2.0×10-161.7×10-32.2×10-110.231.9×10-8Table 2.Relationship between each SDI item and the SF-36 score (p< 1.2×10-3SDI itemPCS scorep-valuePositive(Median (IQR))Negative(Median (IQR))Muscle atrophy/weakness33 (19-45)50 (43-54)3.0×10-10Osteoporosis with fracture/vertebral collapse24 (12-32)49 (38-54)9.7×10-8Claudication31 (19-35)49 (38-54)7.4×10-5Cognitive impairment/psychosis27 (17-33)49 (38-54)9.9×10-5SDI itemMCS scorep-valuePositive(Median (IQR))Negative(Median (IQR))Scarring chronic alopecia42 (29-51)49 (39-54)3.4×10-4Conclusion:We demonstrated that organ damage has negative effects on patient QOL, indicating the importance of preventing irreversible organ damage for maintaining QOL. Moreover, muscle atrophy/weakness, osteoporosis with fracture/vertebral collapse, claudication, cognitive impairment/major psychosis, and scarring chronic alopecia significantly correlated with QOL deterioration, suggesting that these items should be examined with special care in clinical practice.References:[1]Lopez R, et al. Rheumatology (Oxford). 2012; 51:491-498.[2]Gladman D, et al. Arthritis Rheum. 1996; 39:363-369.[3]Fukuhara S, et al. J Clin Epidemiol. 1998; 51:1037-1044.[4]Inoue M, et al. Lupus. 2017; 26:849-856.[5]Grootscholten C, et al. Qual Life Res. 2003; 12:635–644.Disclosure of Interests:Yudai Takase: None declared, Hiroshi Doi: None declared, Takeshi Iwasaki: None declared, Motomu Hashimoto Grant/research support from: Bristol-Myers Squibb, Eisai, and Eli Lilly and Company., Speakers bureau: Bristol-Myers Squibb and Mitsubishi Tanabe Pharma., Ryuta Inaba: None declared, Tomohiro Kozuki: None declared, Masashi Taniguchi: None declared, Yuya Tabuchi Paid instructor for: Astellas Pharma, GlaxoSmithKline, Mitsubishi Tanabe Pharma, and Nippon Shinyaku., Speakers bureau: AbbVie, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Nippon Shinyaku, and Novartis Pharma. (Outside the field of the present study.), Koji Kitagori: None declared, Syuji Akizuki: None declared, Kosaku Murakami Speakers bureau: AbbVie, Eisai, and Mitsubishi Tanabe Pharma., Ran Nakashima Grant/research support from: Takeda Pharmaceutical. (Outside the field of the present study.), Speakers bureau: Astellas Pharma, Medical & Biological Laboratories, AstraZeneca, and Boehringer Ingelheim. (Outside the field of the present study.), Hajime Yoshifuji Grant/research support from: Astellas Pharma. (Outside the field of the present study.), Speakers bureau: Chugai Pharmaceutical. (Outside the field of the present study.), Wataru Yamamoto: None declared, Masao Tanaka Grant/research support from: AbbVie, Asahi Kasei Pharma, Astellas Pharma, Ayumi Pharmaceutical, Chugai Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Taisho Pharmaceutical, and UCB Japan., Speakers bureau: AbbVie, Asahi Kasei Pharma, Astellas Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Eli Lilly and Company, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Novartis Pharma, Pfizer, Taisho Pharmaceutical, Takeda Pharmaceutical, and UCB Japan., Koichiro Ohmura Grant/research support from: Astellas Pharma, AYUMI Pharmaceutical, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Japan Blood Products Organization, Mitsubishi Tanabe Pharma, Nippon Kayaku, Nippon Shinyaku, Sanofi, and Takeda Pharmaceutical., Speakers bureau: AbbVie, Actelion Pharmaceuticals Japan, Asahi Kasei Pharma, AYUMI Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Novartis Pharma, and Sanofi.
Collapse
|
49
|
Murakami K, Hashimoto M, Murata K, Yamamoto W, Hara R, Katayama M, Onishi A, Akashi K, Nagai K, Son Y, Amuro H, Hirano T, Ebina K, Nishitani K, Tanaka M, Ito H, Ohmura K. THU0107 OBESITY PREDICTS RESPONSE TO NOT ALL BUT CERTAIN BIOLOGICAL / TARGETED DISEASE MODIFYING ANTI-RHEUMATIC DRUGS FOR RHEUMATOID ARTHRITIS - RESULTS FROM KANSAI CONSORTIUM FOR WELL-BEING OF RHEUMATIC DISEASE PATIENTS (ANSWER COHORT). Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.799] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:A number of previous reports suggested that obesity is one of the baseline factors indicates refractory to biologic disease-modifying antirheumatic drugs (bDMARDs). However, difference of the significant responses appears on obesity patients depending on each kind of drug is yet unclear. However, it is yet unclear how the significant responses on obesity patients vary on each kind of drug.Objectives:To assess whether obesity affects clinical outcome in rheumatoid arthritis (RA) treated with each molecular-targeted agent including bDMARDs and tofacitinib.Methods:In Kansai consortium for well-being of rheumatic disease patients (ANSWER) cohort, which was the real-world retrospective cohort of clinical database for rheumatic diseases, RA patients who initiated biological / targeted disease modifying anti-rheumatic drugs were included and consecutively followed. Obesity was defined as BMI over than 25, and patients were divided between obese (“Ob”) and non-obese (“non-Ob”) patients. SDAI (simplified disease activity index) was compared between non-Ob and Ob at month 0, 3, 6, 9, 12 after the indicated drugs were administered. Using logistic regression analysis, odds ratio (OR) and their corresponding 95% confidence intervals (95% CIs) were further calculated to estimate achievement rate of SDAI remission defined as lower than 3.3 by obesity and other relevant clinical parameters. Once after the drugs were discontinued by any unfavorable reason, disease activities were no more scored and the Last Observation Carried Forward (LOCF) imputation method was used for SDAI at month 3 and thereafter.Results:A total of 1936 patients met in the inclusion criteria were under the analysis. In each drug, SDAI remission rate (non-Ob, Ob, p-value by Chi-square test) at month 12 was as follows; Infliximab (IFX, n=135): 43%, 38%, NS (not significant); Etanercept (ETN, n=188): 44%, 19%, p=0.0122; Adalimumab (ADA, n=169): 50%, 56%, NS; Golimumab (GLM, n=315): 36%, 30%, NS; Certolizumab pegol (CZP, n=131): 33%, 56%, p=0.0287; Tocilizumab (TCZ, n=423): 41%, 29%, p=0.0456; Abatacept (ABT, n=144): 26%, 23%, NS; Tofacitinib (TOF, n=69): 27%, 23%, NS. In multivariate analysis to predict SDAI remission at month 12, obesity was an independent protective factor in CZP (OR: 0.29, 95% CIs: 0.10 – 0.83), but was an independent risk factor in TCZ (OR: 1.9, 95% CIs: 1.01 – 3.61) irrespective of age, sex, disease duration, SDAI at month 0 or number of previous bDMARDs. Any other drug including ETN did not show significant result between non -Ob and Ob in the multivariate analysis.Conclusion:Obese patients were more resistant to TCZ but more effective in CZP than non-obese patients.References:[1]Ann Rheum Dis. 2018;77(10):1405-1412. Joint Bone Spine. 2019;86(2):173-183.Disclosure of Interests:Kosaku Murakami Speakers bureau: AbbVie, Eisai, and Mitsubishi Tanabe Pharma., Motomu Hashimoto Grant/research support from: Bristol-Myers Squibb, Eisai, and Eli Lilly and Company., Speakers bureau: Bristol-Myers Squibb and Mitsubishi Tanabe Pharma., Koichi Murata Grant/research support from: KMurata belong to a department that has been financially supported by four pharmaceutical companies (Mitsubishi-Tanabe, Chugai, AYUMI and UCB Japan)., Employee of: KMurata belong to a department that has been financially supported by four pharmaceutical companies (Mitsubishi-Tanabe, Chugai, AYUMI and UCB Japan)., Speakers bureau: KMurak has received speaking fees, and/or consulting fees from Eisai Co. Ltd, Chugai Pharmaceutical Co. Ltd., Pfizer Japan Inc, Bristol-Myers Squibb, Mitsubishi-Tanabe Pharma Corporation, UCB, Daiichi Sankyo Co. Ltd. and Astellas Pharma Inc., Wataru Yamamoto: None declared, Ryota Hara Speakers bureau: RH received a speaker fee from AbbVie, Masaki Katayama: None declared, Akira Onishi Speakers bureau: AO received a speaker fee from Chugai, Ono Pharmaceutical, Eli Lilly, Mitsubishi-Tanabe, Asahi-Kasei, and Takeda, Kengo Akashi: None declared, Koji Nagai: None declared, Yonsu Son: None declared, Hideki Amuro: None declared, Toru Hirano Grant/research support from: TH received a research grant and/or speaker fee from Astellas, Chugai, Nippon Shinyaku, Abbvie, Eisai, and Ono Pharmaceutical, Speakers bureau: TH received a research grant and/or speaker fee from Astellas, Chugai, Nippon Shinyaku, Abbvie, Eisai, and Ono Pharmaceutical, Kosuke Ebina Grant/research support from: KE has received research grants from Abbie, Asahi-Kasei, Astellas, Chugai, Eisai, Ono Pharmaceutical, and UCB Japan., Employee of: KE is affiliated with the Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, which is supported by Taisho., Speakers bureau: KE has received payments for lectures from Abbie, Asahi-Kasei, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Janssen, Mitsubishi-Tanabe, Ono Pharmaceutical, Sanofi, and UCB Japan., Kohei Nishitani Grant/research support from: KN belong to a department that has been financially supported by four pharmaceutical companies (Mitsubishi-Tanabe, Chugai, AYUMI and UCB Japan)., Masao Tanaka Grant/research support from: AbbVie, Asahi Kasei Pharma, Astellas Pharma, Ayumi Pharmaceutical, Chugai Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Taisho Pharmaceutical, and UCB Japan., Speakers bureau: AbbVie, Asahi Kasei Pharma, Astellas Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Eli Lilly and Company, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Novartis Pharma, Pfizer, Taisho Pharmaceutical, Takeda Pharmaceutical, and UCB Japan., Hiromu Ito: None declared, Koichiro Ohmura Grant/research support from: Astellas Pharma, AYUMI Pharmaceutical, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Japan Blood Products Organization, Mitsubishi Tanabe Pharma, Nippon Kayaku, Nippon Shinyaku, Sanofi, and Takeda Pharmaceutical., Speakers bureau: AbbVie, Actelion Pharmaceuticals Japan, Asahi Kasei Pharma, AYUMI Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Novartis Pharma, and Sanofi.
Collapse
|
50
|
Katsushima M, Hashimoto M, Shirakashi M, Yoshida T, Yamamoto W, Murakami K, Murata K, Nishitani K, Tanaka M, Ito H, Matsuda S. AB0197 INCREASED CIRCULATING ADIPONECTIN IS AN INDEPENDENT DISEASE ACTIVITY MARKER IN PATIENTS WITH RHEUMATOID ARTHRITIS: A CROSS-SECTIONAL STUDY USING THE KURAMA DATABASE. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Adiponectin is a major adipokine with pleiotropic effects on inflammatory conditions including rheumatoid arthritis (RA). Adiponectin generally has anti-atherogenic effects, and its serum level inversely correlates with body mass index (BMI) and visceral fat area (VFA). On the other hand, several studies have indicated a deleterious role of adiponectin in RA progression [1]. Recently, both low BMI and increased serum adiponectin have been reported as poor prognostic factors of RA [2, 3]. However, large-scale surveys have not been done focusing on both BMI and serum adiponectin, and it is unclear which factor provides further contribution to RA disease activity. In addition, the effects of biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase (JAK) inhibitors on serum adiponectin are largely unknown.Objectives:To clarify the relationship among serum adiponectin, body composition, current disease activity and therapeutic agents of RA.Methods:We conducted a cross-sectional study in RA patients under treatment with agents including bDMARDs and JAK inhibitors. A total of 351 subjects from the Kyoto University RA Management Alliance cohort (KURAMA) were enrolled. We classified the participants into five body composition groups (overweight with or without visceral adiposity, normal with or without visceral adiposity, and underweight), according to the cut-off points for obesity and visceral fat used in Japan: BMI, 18.5 kg/m2for underweight and 25.0 kg/m2for obesity, and VFA, 100 cm2for visceral adiposity. Differences of continuous variables among the five groups were assessed by the Steel-Dwass test or one-way analysis of variance (ANOVA). We adopted a multiple standardized linear regression model to analyze effects of serum adiponectin level on DAS28-ESR.Results:Serum adiponectin levels (20.9±12.5 vs. 14.7±8.4 µg/ml, p < 0.001) and DAS28-ESR (3.04±1.0 vs. 2.63±0.9,p= 0.017) in the underweight group were significantly higher than those in the others. In multiple regression analysis, serum adiponectin level, but not BMI, was positively correlated with DAS28-ESR (estimate = 0.0127,p= 0.0258). Subanalysis also showed that the use of bDMARD or JAK inhibitor did not have an obvious influence on circulating adiponectin.Conclusion:In the multiple regression analysis we revealed a positive and independent correlation between serum adiponectin and DAS28-ESR in Japanese RA patients. Thus, serum adiponectin is an potential marker reflecting high disease activity of RA regardless of current medications.References:[1]Frommer KW, Zimmermann B, Meier FM, Schroder D, Heil M, Schaffler A, et al. Adiponectin-mediated changes in effector cells involved in the pathophysiology of rheumatoid arthritis. Arthritis Rheum. 2010;62(10):2886-99.[2]Kaufmann J, Kielstein V, Kilian S, Stein G, Hein G. Relation between body mass index and radiological progression in patients with rheumatoid arthritis. Journal of Rheumatology. 2003;30(11):2350-5.[3]Ebina K, Fukuhara A, Ando W, Hirao M, Koga T, Oshima K, et al. Serum adiponectin concentrations correlate with severity of rheumatoid arthritis evaluated by extent of joint destruction. Clin Rheumatol. 2009;28(4):445-51.Acknowledgments:We would like to thank to Ms. Sumie Nakagawa for management of blood specimens, Ms. Noriko Kitayama and Ms. Maki Yoneyama for support of the patients. We also thank Drs. Takao Fujii, Chicashi, Terao, Masahide Hamaguchi, Hiroyuki Yoshitomi, and Masahiro Ishikawa for their thoughtful comments.Disclosure of Interests:Masao Katsushima: None declared, Motomu Hashimoto Grant/research support from: Bristol-Myers Squibb, Eisai, and Eli Lilly and Company., Speakers bureau: Bristol-Myers Squibb and Mitsubishi Tanabe Pharma., Mirei Shirakashi: None declared, Tamami Yoshida: None declared, Wataru Yamamoto: None declared, Kosaku Murakami Speakers bureau: AbbVie, Eisai, and Mitsubishi Tanabe Pharma., Koichi Murata Grant/research support from: KMurata belong to a department that has been financially supported by four pharmaceutical companies (Mitsubishi-Tanabe, Chugai, AYUMI and UCB Japan)., Employee of: KMurata belong to a department that has been financially supported by four pharmaceutical companies (Mitsubishi-Tanabe, Chugai, AYUMI and UCB Japan)., Speakers bureau: KMurak has received speaking fees, and/or consulting fees from Eisai Co. Ltd, Chugai Pharmaceutical Co. Ltd., Pfizer Japan Inc, Bristol-Myers Squibb, Mitsubishi-Tanabe Pharma Corporation, UCB, Daiichi Sankyo Co. Ltd. and Astellas Pharma Inc., Kohei Nishitani Grant/research support from: KN belong to a department that has been financially supported by four pharmaceutical companies (Mitsubishi-Tanabe, Chugai, AYUMI and UCB Japan)., Masao Tanaka Grant/research support from: AbbVie, Asahi Kasei Pharma, Astellas Pharma, Ayumi Pharmaceutical, Chugai Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Taisho Pharmaceutical, and UCB Japan.Speakers bureau: AbbVie, Asahi Kasei Pharma, Astellas Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Eli Lilly and Company, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Novartis Pharma, Pfizer, Taisho Pharmaceutical, Takeda Pharmaceutical, and UCB Japan., Hiromu Ito: None declared, Shuichi Matsuda: None declared
Collapse
|